<SEC-DOCUMENT>0000939767-24-000149.txt : 20241029
<SEC-HEADER>0000939767-24-000149.hdr.sgml : 20241029
<ACCEPTANCE-DATETIME>20241029160744
ACCESSION NUMBER:		0000939767-24-000149
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		16
CONFORMED PERIOD OF REPORT:	20241029
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20241029
DATE AS OF CHANGE:		20241029

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			EXELIXIS, INC.
		CENTRAL INDEX KEY:			0000939767
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				043257395
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0103

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30235
		FILM NUMBER:		241405748

	BUSINESS ADDRESS:	
		STREET 1:		1851 HARBOR BAY PARKWAY
		CITY:			ALAMEDA
		STATE:			CA
		ZIP:			94502
		BUSINESS PHONE:		6508377000

	MAIL ADDRESS:	
		STREET 1:		1851 HARBOR BAY PARKWAY
		CITY:			ALAMEDA
		STATE:			CA
		ZIP:			94502

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EXELIXIS INC
		DATE OF NAME CHANGE:	20000207

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EXELIXIS PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	20000106
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>exel-20241029.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:b3915185-4d70-4139-b9e4-6aa0964ddf94,g:a123f1e6-6f11-4d51-8130-aa9d378b2a84,d:c28c206964c54608b7cfd2ba1aae1f8a-->
<html xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns="http://www.w3.org/1999/xhtml" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>exel-20241029</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-month-day-year" id="f-21">10/29/2024</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-22">0000939767</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" id="f-23">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="exel-20241029.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-29</xbrli:startDate><xbrli:endDate>2024-10-29</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ic28c206964c54608b7cfd2ba1aae1f8a_1"></div><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:16pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:16pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:200.25pt"><tr><td style="width:1.0pt"/><td style="width:108.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.00pt"/><td style="width:1.0pt"/></tr><tr style="height:20pt"><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:16pt;font-weight:700;line-height:100%">FORM</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:16pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">8-K</ix:nonNumeric></span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CURRENT REPORT </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO SECTION 13 OR 15(d) OF THE </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECURITIES EXCHANGE ACT OF 1934 </span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Date of Report (Date of earliest event reported): <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-2">October 29, 2024</ix:nonNumeric></span></div><div style="margin-top:9pt;text-align:center"><span><br/></span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:200.25pt"><tr><td style="width:1.0pt"/><td style="width:198.25pt"/><td style="width:1.0pt"/></tr><tr style="height:47pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"><div style="text-align:center"><img src="exel-20241029_g1.jpg" alt="Exelixis_Logo_RGB_2023.jpg" style="height:47px;margin-bottom:5pt;vertical-align:text-bottom;width:177px"/></div></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:16pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-3">EXELIXIS, INC.</ix:nonNumeric></span></div></td></tr><tr style="height:12pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Exact name of registrant as specified in its charter)</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.619%"><tr><td style="width:1.0%"/><td style="width:38.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.174%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:39.145%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-4">Delaware</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">000-30235</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-6">04-3257395</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(State or Other Jurisdiction of Incorporation)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Commission File Number)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(IRS Employer Identification No.)</span></div></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-7">1851 Harbor Bay Parkway</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-8">Alameda</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-9">California</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-10">94502</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Address of principal executive offices) (Zip Code)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-11">650</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-12">837-7000</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Registrant&#8217;s telephone number, including area code) </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): </span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="f-13">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="f-14">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="f-15">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="f-16">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </span></div><div><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section&#160;12(b) of the Act:</span></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.553%"><tr><td style="width:1.0%"/><td style="width:39.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.780%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:38.363%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 5.5pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 5.5pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-17">Common Stock $0.001 Par Value per Share</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-18">EXEL</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-19">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter). Emerging growth company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="f-20">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ic28c206964c54608b7cfd2ba1aae1f8a_7"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.02.  Results of Operations and Financial Condition.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October&#160;29, 2024, Exelixis, Inc. (Exelixis) issued a press release announcing its financial results for the quarter ended September&#160;27, 2024, and providing a corporate update. A copy of such press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information in this report, including the exhibit hereto, shall not be deemed &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this report and in the accompanying exhibit shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by Exelixis, whether made before or after the date hereof, regardless of any general incorporation language in such filing. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.01.  Financial Statements and Exhibits.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(d) &#160;&#160;&#160;&#160;Exhibits.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.553%"><tr><td style="width:1.0%"/><td style="width:8.914%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.995%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:33.429%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.995%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:51.967%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit Number</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit Description</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exel20240930exhibit991.htm">Press Release issued October 29, 2024</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ic28c206964c54608b7cfd2ba1aae1f8a_10"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </span></div><div style="margin-top:5pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.428%"><tr><td style="width:1.0%"/><td style="width:26.608%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:54.526%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">E</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">XELIXIS, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">NC.</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 29, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Jeffrey J. Hessekiel</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Jeffrey J. Hessekiel</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President and General Counsel <br/></span></td></tr></table></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exel20240930exhibit991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="id5623c8f2640433e8a383cb4f5b2faba_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit 99.1</font></div></div><div style="margin-top:9pt"><img alt="imagea.jpg" src="imagea.jpg" style="height:47px;margin-bottom:5pt;vertical-align:text-bottom;width:175px"></div><div style="text-align:justify"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Contacts&#58;</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Chris Senner</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Chief Financial Officer</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Exelixis, Inc.</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">650-837-7240</font></div><div style="text-align:right"><font style="color:#006ba6;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">csenner&#64;exelixis.com</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Varant Shirvanian</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%">Director, Investor Relations</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Exelixis, Inc.</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">650-837-7917</font></div><div style="text-align:right"><font style="color:#006ba6;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%;text-decoration:underline">vshirvanian&#64;exelixis.com</font></div><div style="text-align:center"><font><br></font></div><div style="margin-top:9pt;text-align:center;text-indent:36pt"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exelixis Announces Third Quarter 2024 Financial Results and Provides Corporate Update</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:3pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">- Total Revenues of $539.5 million, Cabozantinib Franchise U.S. Net Product Revenues of $478.1 million -</font></div><div style="margin-bottom:3pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">- GAAP Diluted EPS of $0.40, Non-GAAP Diluted EPS of $0.47 -</font></div><div style="margin-bottom:3pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">- Increasing Total Revenues and Net Product Revenues Guidance -</font></div><div style="margin-bottom:3pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:115%">- Favorable Ruling on Cabozantinib Patent Litigation Received from U.S. District Court -</font></div><div style="margin-bottom:3pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">- Collaboration with Merck Expands Zanzalintinib Development Program -</font></div><div style="margin-bottom:3pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">- Conference Call and Webcast Today at 5&#58;00 PM Eastern Time -</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">ALAMEDA, Calif. &#8211; October&#160;29, 2024 - Exelixis, Inc. (Nasdaq&#58; EXEL) today reported financial results for the third quarter of 2024, provided an update on progress toward achieving key corporate objectives, and detailed its recent and anticipated commercial, clinical and pipeline development milestones.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;The favorable ruling on our cabozantinib intellectual property estate and recently announced zanzalintinib development collaboration with Merck have generated important momentum to drive future growth across all components of our business,&#8221; said Michael M. Morrissey, Ph.D., President and CEO, Exelixis. &#8220;We are increasing 2024 full year guidance for total and net product U.S. revenues based on the strong commercial performance of the cabozantinib franchise in the third quarter. We continue to execute on our plans for potential cabozantinib label expansions in neuroendocrine tumors and prostate cancer, with the final results from CABINET published in </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">The New England Journal of Medicine</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> in September and our partner Ipsen&#8217;s regulatory submission in Europe.&#8221; </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Dr. Morrissey continued&#58; &#8220;Importantly, the zanzalintinib development program, which is now the subject of six ongoing or planned phase 3 pivotal trials, including two new renal cell carcinoma studies as part of our collaboration with Merck, headlines our emerging pipeline of novel agents with the potential to improve standards of care for patients with cancer. At the same time, we are accelerating our early-stage clinical pipeline with XL309, XB010 and XL495 in phase 1 development. I want to thank everyone at Exelixis for their hard work and dedication as we continue driving value for shareholders and innovating on behalf of the patients we serve.&#8221;</font></div><div style="text-align:justify"><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;- more - </font></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.899%"><tr><td style="width:1.0%"></td><td style="width:57.957%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exelixis Third Quarter 2024 Financial Results</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Page 2 of 9</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">October&#160;29, 2024</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Third Quarter 2024 Financial Results</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Total revenues </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">for the quarter ended September&#160;30, 2024</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">were $539.5&#160;million, as compared to $471.9&#160;million for the comparable period in 2023. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total revenues for the quarter ended September&#160;30, 2024 included net product revenues of $478.1 million, as compared to $426.5&#160;million for the comparable period in 2023. The increase in net product revenues was primarily due to an increase in sales volume and average net selling price.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Collaboration revenues, composed of license revenues and collaboration services revenues, were $61.5&#160;million for the quarter ended September&#160;30, 2024, as compared to $45.4&#160;million for the comparable period in 2023. The increase in collaboration revenues was primarily related to an increase in milestone-related revenues recognized in the quarter and higher royalty revenues for the sales of cabozantinib outside of the U.S. generated by Exelixis&#8217; collaboration partners, Ipsen Pharma SAS (Ipsen) and Takeda Pharmaceutical Company Limited, partially offset by a decrease in development cost reimbursements earned. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Research and development expenses</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> for the quarter ended September&#160;30, 2024 were $222.6&#160;million, as compared to $332.6&#160;million for the comparable period in 2023. The decrease in research and development expenses was primarily related to decreases in license and other collaboration costs.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Selling, general and administrative expenses</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> for the quarter ended September&#160;30, 2024 were $111.8&#160;million, as compared to $138.1 million for the comparable period in 2023. The decrease in selling, general and administrative expenses was primarily related to decreases in corporate giving, stock-based compensation expenses and legal and advisory fees.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Impairment of long-lived assets </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">for the quarter ended September&#160;30, 2024 of $51.7&#160;million was related to the non-cash asset impairment charge to certain of Exelixis&#8217; leased facilities which are currently not in use and may be subleased.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Provision for income taxes </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">for the quarter ended September&#160;30, 2024 was $36.8 million, as compared to $4.8&#160;million for the comparable period in 2023.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:103%">GAAP net income </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:103%">for the quarter ended September&#160;30, 2024 was $118.0&#160;million, or $0.41 per share, basic and $0.40 per share, diluted, as compared to GAAP net income of $1.0&#160;million, or $0.00 per share, basic and diluted, for the comparable period in 2023. GAAP net income per share for the quarter ended September&#160;30, 2024 was favorably impacted by lower weighted-average common shares outstanding for the quarter ended September&#160;30, 2024, as compared to the comparable period in 2023, as a result of the stock repurchase programs.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Non-GAAP net income </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">for the quarter ended September&#160;30, 2024 was $135.7&#160;million, or $0.47&#160;per share, basic and diluted, as compared to non-GAAP net income of $32.1&#160;million, or $0.10&#160;per share, basic and diluted, for the comparable period in 2023. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Non-GAAP Financial Measures</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">To supplement Exelixis&#8217; financial results presented in accordance with U.S. Generally Accepted Accounting Principles (GAAP), Exelixis presents non-GAAP net income (and the related per share measures), which excludes from GAAP net income (and the related per share measures) stock-based compensation expense, adjusted for the related income tax effect for all periods presented. </font></div><div style="text-align:justify"><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;- more - </font></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.899%"><tr><td style="width:1.0%"></td><td style="width:57.957%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exelixis Third Quarter 2024 Financial Results</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Page 3 of 9</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">October&#160;29, 2024</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Exelixis believes that the presentation of these non-GAAP financial measures provides useful supplementary information to, and facilitates additional analysis by, investors. In particular, Exelixis believes that these non-GAAP financial measures, when considered together with its financial information prepared in accordance with GAAP, can enhance investors&#8217; and analysts&#8217; ability to meaningfully compare Exelixis&#8217; results from period to period, and to identify operating trends in Exelixis&#8217; business. Exelixis has excluded stock-based compensation expense, adjusted for the related income tax effect, because it is a non-cash item that may vary significantly from period to period as a result of changes not directly or immediately related to the operational performance for the periods presented. Exelixis also regularly uses these non-GAAP financial measures internally to understand, manage and evaluate its business and to make operating decisions.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">These non-GAAP financial measures are in addition to, not a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP. Exelixis encourages investors to carefully consider its results under GAAP, as well as its supplemental non-GAAP financial information and the reconciliation between these presentations, to more fully understand Exelixis&#8217; business. Reconciliations between GAAP and non-GAAP results are presented in the tables of this release.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">2024 Financial Guidance</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Exelixis is providing the following updated financial guidance for fiscal year 2024</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">(1)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.292%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.703%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.705%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Current Guidance</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(provided on October 29, 2024)</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Previous Guidance</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(provided on August 6, 2024)</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total revenues</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline"> </font></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$2.150 billion - $2.200 billion</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$1.975 billion - $2.075 billion</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Net product revenues</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">(2)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$1.775 billion - $1.825 billion</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$1.650 billion - $1.750 billion</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Cost of goods sold</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#126;4.5% of net product revenues</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4% - 5% of net product revenues</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Research and development expenses</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$925 million - $950 million</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">(3)</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$925 million - $975 million</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">(4)</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">(5)</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$475 million - $500 million</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$450 million - $500 million</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Effective tax rate</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">21% - 22%</font></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">20% - 22%</font></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">____________________</font></div><div style="padding-left:7.2pt;text-indent:-7.2pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1) </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2024 financial guidance excludes expenses related to the restructuring plan announced in January 2024 and impairment of long-lived assets announced in October 2024.</font></div><div style="margin-bottom:1pt;margin-top:1pt;padding-left:7.2pt;text-indent:-7.2pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2) </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Exelixis&#8217; 2024 net product revenues guidance range includes the impact of a U.S. wholesale acquisition cost increase of 2.2% for both CABOMETYX and COMETRIQ effective on January 1, 2024.</font></div><div style="margin-bottom:1pt;margin-top:1pt;padding-left:7.2pt;text-indent:-7.2pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3) </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Includes $30 million of non-cash stock-based compensation expense.</font></div><div style="margin-bottom:1pt;margin-top:1pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(4) </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Includes $40 million of non-cash stock-based compensation expense.</font></div><div style="margin-bottom:1pt;margin-top:1pt;padding-left:7.2pt;text-indent:-7.2pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(5) </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Includes $60 million of non-cash stock-based compensation expense.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Corporate Highlights</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Favorable Ruling in Second Cabozantinib Abbreviated New Drug Application (ANDA) Litigation Against MSN Pharmaceuticals, Inc. (MSN). </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In October, </font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">the U.S. District Court for the District of Delaware (the District Court) ruled in Exelixis&#8217; favor, </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">rejecting MSN&#8217;s challenge to three Orange Book-listed patents related to cabozantinib (U.S. Patents No. 11,091,439 (crystalline salt forms), 11,091,440 (pharmaceutical composition) and 11,098,015 (methods of treatment)), which expire January 15, 2030. </font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The District Court&#8217;s decision follows an earlier stipulation that MSN&#8217;s proposed generic cabozantinib product (ANDA No. 213878) infringes the &#8217;439, &#8217;440, and &#8217;015 patents. T</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">he District Court also ruled that Exelixis&#8217; U.S. Patent No. 11,298,349 (pharmaceutical composition) is not invalid and not infringed by MSN&#8217;s proposed ANDA product. </font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">To Exelixis&#8217; knowledge, the U.S. Food and </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;- more - </font></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.899%"><tr><td style="width:1.0%"></td><td style="width:57.957%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exelixis Third Quarter 2024 Financial Results</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Page 4 of 9</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">October&#160;29, 2024</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Drug Administration (FDA) has not yet granted tentative approval of MSN&#8217;s proposed ANDA product. </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On October 23, 2024, the District Court entered final judgment reflecting the opinion. Based on the District Court&#8217;s final judgment, should the FDA ultimately approve MSN&#8217;s ANDA, the effective date of any such approval and commercial </font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">launch in the U.S. of MSN&#8217;s proposed ANDA product shall not be a date earlier than January 15, 2030, subject to Exelixis&#8217; potential additional regulatory exclusivity. </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The District Court&#8217;s judgment is also</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> subject to appeal</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> by either party</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">New Clinical Development Collaboration with Merck to Evaluate Zanzalintinib in Combination with KEYTRUDA&#174; (pembrolizumab) in Head and Neck Cancer and with WELIREG&#174; (belzutifan) in Renal Cell Carcinoma (RCC).</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> In October, Exelixis and Merck (known as MSD outside of the U.S. and Canada) announced a clinical development collaboration to evaluate zanzalintinib in combination with KEYTRUDA in head and neck squamous cell carcinoma (HNSCC), and zanzalintinib with WELIREG in RCC. Under the terms of the collaboration, Merck will supply KEYTRUDA, its anti-PD-1 therapy, for the ongoing, Exelixis-sponsored phase 3 STELLAR-305 pivotal trial in previously untreated PD-L1 positive recurrent or metastatic HNSCC. In addition, Merck will sponsor a phase 1&#47;2 trial and two phase 3 pivotal trials evaluating zanzalintinib in combination with WELIREG, its oral hypoxia-inducible factor-2 alpha (HIF-2&#945;) inhibitor, in RCC. Merck will fund one of these phase 3 studies, and Exelixis will co-fund the phase 1&#47;2 trial and the other phase 3 study, as well as supply zanzalintinib and cabozantinib. Exelixis maintains all global commercial and marketing rights to zanzalintinib.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Stock Repurchase Program. </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In August, Exelixis announced that the company&#8217;s Board of Directors authorized the repurchase of up to $500 million of the company&#8217;s common stock through the end of 2025, the third stock repurchase program undertaken by Exelixis since March 2023. Under this program, as of September 30, 2024, Exelixis has repurchased $12.4 million of the company&#8217;s common stock, at an average price of $25.61 per share.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Cabozantinib Highlights</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Cabozantinib Franchise Net Product Revenues and Royalties. </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Net product revenues generated by the cabozantinib franchise in the U.S. were $478.1&#160;million during the third quarter of 2024, with net product revenues of $475.7&#160;million from CABOMETYX&#174; (cabozantinib) and $2.4&#160;million from COMETRIQ&#174; (cabozantinib). Based upon cabozantinib-related net product revenues generated by Exelixis&#8217; collaboration partners during the quarter ended September&#160;30, 2024, Exelixis earned $41.8&#160;million in royalty revenues. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exelixis&#8217; Partner Ipsen Opted into Phase 3 CABINET Pivotal Trial in Advanced Neuroendocrine Tumors (NET) and Submitted an Extension of Indication Marketing Authorization to the European Medicines Agency (EMA).</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> In July, Ipsen announced it opted into the phase 3 CABINET pivotal trial, expanding the existing collaboration and license agreement with Exelixis and permitting Ipsen to seek potential marketing authorizations for CABOMETYX in advanced pancreatic NET (pNET) and extra-pancreatic NET (epNET) from regulatory authorities outside of the U.S. and Japan. As part of the agreement, Exelixis is eligible to receive reimbursement of a portion of costs related to the trial, as well as milestone payments for potential future regulatory action by the EMA. In September, Ipsen announced it submitted an extension of indication Marketing Authorization to the EMA for CABOMETYX in advanced NET. These announcements were based on detailed results from CABINET, which evaluated cabozantinib compared with placebo in patients with previously treated advanced pNET and advanced epNET.</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> CABINET is sponsored by the National Cancer Institute (NCI), part of the National Institutes of Health, and led by the NCI-funded Alliance for Clinical Trials in Oncology</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">FDA Accepted Supplemental New Drug Application (sNDA) for Cabozantinib for Patients with Advanced NET. </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In August, Exelixis announced that the FDA accepted its sNDA for cabozantinib for patients with previously treated advanced pNET and for patients with previously treated advanced epNET. The FDA assigned a standard review with a Prescription Drug User Fee Act (PDUFA) target action date of April 3, 2025. The FDA also granted </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;- more - </font></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.899%"><tr><td style="width:1.0%"></td><td style="width:57.957%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exelixis Third Quarter 2024 Financial Results</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Page 5 of 9</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">October&#160;29, 2024</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">orphan drug designation to cabozantinib for the treatment of pNET. The sNDA was based on results from the CABINET trial</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Final Results from Phase 3 CABINET Pivotal Trial Evaluating Cabozantinib in Advanced NET Presented at the 2024 European Society for Medical Oncology (ESMO) Congress and Published in </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">The</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">New England Journal of Medicine</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> (</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">NEJM</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">). </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In September, detailed final results from CABINET were presented at the 2024 ESMO Congress and published in </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">NEJM</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The results demonstrated continued improvement with cabozantinib in the primary endpoint of progression-free survival by blinded independent central review, and additional analyses suggest benefits with cabozantinib across all clinical subgroups examined, including primary tumor site, grade and prior systemic anti-cancer therapy. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Final Overall Survival (OS) Results from </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> (mCRPC) Presented </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">at the 2024 ESMO Congress</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">. </font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In September, the final analysis of OS from the </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">phase 3 CONTACT-02 pivotal study was presented at the 2024 ESMO Congress. The results of the final OS analysis showed a trend that favored the combination of cabozantinib and atezolizumab but was not statistically significant. The trend in OS benefit was consistently observed in key subgroups, including in patients with liver metastases, a subgroup of mCRPC patients with the poorest prognosis in need of new treatment options, which Exelixis anticipates will grow in the coming years. CONTACT-02 evaluated cabozantinib in combination with atezolizumab compared with a second novel hormonal therapy (NHT) in patients with measurable, extra-pelvic mCRPC who have progressed after treatment with one prior NHT. Exelixis intends to submit an sNDA to the FDA for cabozantinib in combination with atezolizumab for mCRPC in the fourth quarter of 2024.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Pipeline Highlights</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Enrollment Completion for Zanzalintinib Phase 3 STELLAR-303 Study in Metastatic Colorectal Cancer (CRC) and Announcement of STELLAR-311 Pivotal Trial Evaluating Zanzalintinib in NET. </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In August, Exelixis announced that enrollment was completed in the STELLAR-303 phase 3 pivotal study. STELLAR-303 is evaluating zanzalintinib in combination with atezolizumab compared with regorafenib in patients with metastatic refractory CRC that is not microsatellite instability-high or mismatch repair-deficient. The primary endpoint in the study is OS in the patients without liver metastases. Exelixis anticipates preliminary results from the study in 2025. Additionally, Exelixis announced plans to initiate STELLAR-311, a new phase 3 pivotal trial evaluating zanzalintinib compared with everolimus as a first oral therapy in patients with advanced NET, regardless of site of origin, in the first half of 2025.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Initiation of Phase 1 Clinical Trial Evaluating XB010 in Patients with Advanced Solid Tumors.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> In August, Exelixis announced the initiation of the dose-escalation stage of the first-in-human phase 1 clinical trial of XB010 in patients with locally advanced or metastatic solid tumors. XB010, an antibody-drug conjugate (ADC) consisting of a monomethyl auristatin E payload conjugated to a monoclonal antibody targeting the tumor antigen 5T4, is the first custom ADC generated through Exelixis&#8217; biotherapeutics collaboration network. The dose-escalation stage of this global phase 1 study is evaluating XB010 as a single agent and in combination with pembrolizumab to inform the cohort-expansion stage. The expansion cohorts are designed to further assess the tolerability and activity of monotherapy and of the combination in specific indications.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Initiation of Phase 1 Clinical Trial Evaluating XL495 in Patients with Advanced Solid Tumors. </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Today, Exelixis announced the initiation of the dose-escalation stage of the first-in-human phase 1 clinical trial of XL495 in patients with advanced solid tumors. XL495 is a novel, potent, small molecule inhibitor of PKMYT1. The dose-escalation stage of this phase 1 study is designed to determine the maximum tolerated dose of XL495. The expansion cohorts are designed to further assess the tolerability and activity of XL495 both as monotherapy and  in combination with select cytotoxic agents in tumor-specific indications.</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;- more - </font></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.899%"><tr><td style="width:1.0%"></td><td style="width:57.957%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exelixis Third Quarter 2024 Financial Results</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Page 6 of 9</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">October&#160;29, 2024</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Basis of Presentation</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Exelixis has adopted a 52- or 53-week fiscal year that generally ends on the Friday closest to December&#160;31. For convenience, references in this press release as of and for the fiscal periods ended September&#160;27, 2024 and September 29, 2023, are indicated as being as of and for the periods ended</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">September&#160;30, 2024 and September 30, 2023</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Conference Call and Webcast</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Exelixis management will discuss the company&#8217;s financial results for the third quarter of 2024 and provide a general business update during a conference call beginning at 5&#58;00&#160;p.m. ET &#47; 2&#58;00&#160;p.m. PT today, Tuesday, October&#160;29, 2024.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">To access the conference call, please register using this </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">link</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Upon registration, a dial-in number and unique PIN will be provided to join the call. To access the live webcast link, log onto </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">www.exelixis.com</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> and proceed to the Event Calendar page under the Investors &#38; News heading. A webcast replay of the conference call will also be archived on </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">www.exelixis.com</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> for one year.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">About Exelixis</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Exelixis is a globally ambitious oncology company innovating next-generation medicines and regimens at the forefront of cancer care. Powered by drug discovery and development excellence, we are rapidly evolving our product portfolio to target an expanding range of tumor types and indications with our clinically differentiated pipeline of small molecules, antibody-drug conjugates and other biotherapeutics. This comprehensive approach harnesses decades of robust investment in our science and partnerships to advance our investigational programs and extend the impact of our flagship commercial product, CABOMETYX&#174; (cabozantinib). Exelixis is driven by a bold scientific pursuit to create transformational treatments that give more patients hope for the future. For information about the company and its mission to help cancer patients recover stronger and live longer, visit </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">www.exelixis.com</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, follow &#64;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">ExelixisInc</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> on X (Twitter), like </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Exelixis, Inc.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> on Facebook and follow </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Exelixis</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> on LinkedIn. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Forward-Looking Statements</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This press release contains forward-looking statements, including, without limitation, statements related to&#58; Exelixis&#8217; belief that the favorable ruling on its cabozantinib intellectual property estate and zanzalintinib development collaboration with Merck have generated important momentum to drive future growth across all components of the company&#8217;s business&#59; Exelixis&#8217; plans for cabozantinib label expansions in NET and prostate cancer&#59; the potential for Exelixis&#8217; zanzalintinib development program (including new planned pivotal trials), along with the rest of the company&#8217;s emerging pipeline, to improve standards of care for patients with cancer&#59; Exelixis&#8217; updated 2024 financial guidance&#59; the timing of any regulatory approval and commercial launch in the U.S. of MSN&#8217;s proposed ANDA product or other proposed ANDA products, with consideration given to Exelixis&#8217; potential additional regulatory exclusivity and future appeals of the District Court&#8217;s judgment by either party&#59; Exelixis&#8217; immediate and future financial and other obligations under its clinical development collaboration with Merck&#59; Exelixis&#8217; plans to repurchase up to an additional $500 million of its common stock before the end of 2025&#59; Exelixis&#8217; expectation to receive reimbursement payments from Ipsen relating to CABINET, as well as milestone payments for potential future regulatory actions by the EMA&#59; the regulatory review process with respect to Exelixis&#8217; sNDA for cabozantinib in advanced NET, including the PDUFA target action date assigned by the FDA&#59; Exelixis&#8217; plans to submit an sNDA for the combination of cabozantinib and atezolizumab in mCRPC to the FDA during the fourth quarter of 2024 based on the results of CONTACT-02&#59; Exelixis&#8217; expectation for </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;- more - </font></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.899%"><tr><td style="width:1.0%"></td><td style="width:57.957%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exelixis Third Quarter 2024 Financial Results</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Page 7 of 9</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">October&#160;29, 2024</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">preliminary results from STELLAR-303 in 2025&#59; Exelixis&#8217; plans to initiate STELLAR-311 in the first half of 2025&#59; and Exelixis&#8217; scientific pursuit to create transformational treatments that give more patients hope for the future. Any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements and are based upon Exelixis&#8217; current plans, assumptions, beliefs, expectations, estimates and projections. Forward-looking statements involve risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in the forward-looking statements as a result of these risks and uncertainties, which include, without limitation&#58; the degree of market acceptance of CABOMETYX and other Exelixis products in the indications for which they are approved and in the territories where they are approved, and Exelixis&#8217; and its partners&#8217; ability to obtain or maintain coverage and reimbursement for these products&#59; the effectiveness of CABOMETYX and other Exelixis products in comparison to competing products&#59; the level of costs associated with Exelixis&#8217; commercialization, research and development, in-licensing or acquisition of product candidates, and other activities&#59; Exelixis&#8217; ability to maintain and scale adequate sales, marketing, market access and product distribution capabilities for its products or to enter into and maintain agreements with third parties to do so&#59; the availability of data at the referenced times&#59; the potential failure of cabozantinib, zanzalintinib and other Exelixis product candidates, both alone and in combination with other therapies, to demonstrate safety and&#47;or efficacy in clinical testing&#59; uncertainties inherent in the drug discovery and product development process&#59; Exelixis&#8217; dependence on its relationships with its collaboration partners, including their pursuit of regulatory approvals for partnered compounds in new indications, their adherence to their obligations under relevant collaboration agreements and the level of their investment in the resources necessary to complete clinical trials or successfully commercialize partnered compounds in the territories where they are approved&#59; complexities and the unpredictability of the regulatory review and approval processes in the U.S. and elsewhere&#59; Exelixis&#8217; continuing compliance with applicable legal and regulatory requirements&#59; unexpected concerns that may arise as a result of the occurrence of adverse safety events or additional data analyses of clinical trials evaluating cabozantinib and other Exelixis product candidates&#59; Exelixis&#8217; dependence on third-party vendors for the development, manufacture and supply of its products and product candidates&#59; Exelixis&#8217; ability to protect its intellectual property rights&#59; market competition, including the potential for competitors to obtain approval for generic versions of Exelixis&#8217; marketed products&#59; changes in economic and business conditions&#59; and other factors detailed from time to time under the caption &#8220;Risk Factors&#8221; in Exelixis&#8217; most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q, and in Exelixis&#8217; other future filings with the Securities and Exchange Commission. All forward-looking statements in this press release are based on information available to Exelixis as of the date of this press release, and Exelixis undertakes no obligation to update or revise any forward-looking statements contained herein, except as required by law.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Exelixis, the Exelixis logo, CABOMETYX and COMETRIQ are registered trademarks of Exelixis, Inc.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:115%">KETRUDA&#174; and WELIREG&#174; are registered trademarks of Merck Sharp &#38; Dohme LLC,  </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">a subsidiary of Merck &#38; Co., Inc., Rahway, N.J., USA.</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">-see attached financial tables-</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;- more - </font></td></tr></table></div></div></div><div id="id5623c8f2640433e8a383cb4f5b2faba_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.899%"><tr><td style="width:1.0%"></td><td style="width:57.957%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exelixis Third Quarter 2024 Financial Results</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Page 8 of 9</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">October&#160;29, 2024</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">EXELIXIS, INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF INCOME </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(in thousands, except per share amounts)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(unaudited)</font></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.255%"><tr><td style="width:1.0%"></td><td style="width:36.831%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.192%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.399%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.192%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.399%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.399%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.746%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended September 30,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Revenues&#58;</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Net product revenues</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">478,059&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">426,497&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,294,163&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,199,543&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">License revenues</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">60,239&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">42,367&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">299,901&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">133,406&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Collaboration services revenues</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,244&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3,056&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7,882&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">17,607&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total revenues</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">539,542&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">471,920&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,601,946&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,350,556&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Operating expenses&#58;</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Cost of goods sold</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">17,328&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">18,774&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">56,251&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">50,794&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Research and development</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">222,570&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">332,585&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">661,406&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">799,401&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Selling, general and administrative</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">111,801&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">138,144&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">357,800&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">411,264&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;Impairment of long-lived assets</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">51,672&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">51,672&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Restructuring</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">96&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">33,406&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total operating expenses</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">403,467&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">489,503&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,160,535&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,261,459&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Income (loss) from operations</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">136,075&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(17,583)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">441,411&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">89,097&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Interest income</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">18,709&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">23,112&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">55,861&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">65,155&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Other income (expense), net</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(29)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">289&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(405)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">230&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Income before income taxes</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">154,755&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5,818&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">496,867&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">154,482&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Provision for income taxes</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">36,782&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4,777&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">115,461&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">32,235&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;text-indent:18pt;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Net income</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">117,973&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,041&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">381,406&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">122,247&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Net income per share&#58;</font></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.25pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Basic</font></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.41&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.00&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.31&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.38&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Diluted</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.40&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.00&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.28&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.38&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Basic</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">285,622&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">315,496&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">291,865&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">321,373&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Diluted</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">291,478&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">319,247&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">296,994&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">324,277&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;- more - </font></td></tr></table></div></div></div><div id="id5623c8f2640433e8a383cb4f5b2faba_7"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.899%"><tr><td style="width:1.0%"></td><td style="width:57.957%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exelixis Third Quarter 2024 Financial Results</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Page 9 of 9</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">October&#160;29, 2024</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">EXELIXIS, INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">RECONCILIATION OF GAAP NET INCOME TO NON-GAAP NET INCOME </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(in thousands, except per share amounts)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(unaudited)</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.227%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.227%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.780%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.784%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended September 30,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">GAAP net income</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">117,973&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,041&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">381,406&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">122,247&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Adjustments&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Stock-based compensation - research and development expenses</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8,764&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12,438&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">21,834&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">25,279&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Stock-based compensation - selling, general and administrative expenses</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14,259&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">28,040&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">45,656&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">56,760&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Income tax effect of the above adjustments</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(5,335)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(9,420)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(15,624)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(19,062)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Non-GAAP net income</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">135,661&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">32,099&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">433,272&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">185,224&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">GAAP net income per share&#58;</font></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Basic</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.41&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.00&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.31&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.38&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Diluted&#160;</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.40&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.00&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.28&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.38&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Non-GAAP net income per share&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Basic</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.47&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.10&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.48&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.58&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Diluted </font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.47&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.10&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.46&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.57&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Basic</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">285,622&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">315,496&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">291,865&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">321,373&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Diluted</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">291,478&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">319,247&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">296,994&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">324,277&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">____________________</font></div><div style="padding-left:7.2pt;text-indent:-7.2pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1) </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-cash stock-based compensation expense used for GAAP reporting in accordance with Accounting Standards Codification Topic 718, </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Compensation&#8212;Stock Compensation</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</font></div><div style="padding-left:18pt;text-indent:-18pt"><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>exel-20241029.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:b3915185-4d70-4139-b9e4-6aa0964ddf94,g:a123f1e6-6f11-4d51-8130-aa9d378b2a84-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:exel="http://www.exelixis.com/20241029" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.exelixis.com/20241029">
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="exel-20241029_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="exel-20241029_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.exelixis.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>exel-20241029_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:b3915185-4d70-4139-b9e4-6aa0964ddf94,g:a123f1e6-6f11-4d51-8130-aa9d378b2a84-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_0c342f6c-ecd5-4c32-badc-f59880a4daa5_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_f726d4c8-b39a-4d7a-a330-949d4cc86082_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_50fd9aac-6cba-4e5b-aadf-4d80443eb829_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_c7845a47-9967-4163-bd03-c0c05b99cf41_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_aa11e592-ce70-4653-be05-3588cdd4cddd_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_b53fec64-9af7-49e2-b560-6f704ee9c283_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_87947e55-6a0b-4b9e-b2ce-be9fe2df5964_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_728f1663-6c1d-48b2-91fe-cdb5a72f9288_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_b1c21104-a33e-4bcb-8160-359af7c4df63_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_2bf4c390-1150-4afb-bb47-326d02908e1e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_77ddb3e8-cfcd-4f16-81e8-423bbfaf180f_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_75120256-d3dc-499e-9eae-66b650fd4437_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_7e04ab81-dfeb-4971-9a35-317253aaa288_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_a73add89-005b-4812-8c6f-308123814653_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_93909d44-77ef-4663-a996-ddb57a88e152_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_d445c04d-03b9-46a8-bdee-6c4e6447bd00_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_99a9c6fa-4acc-478c-acb9-3b1f77e72c76_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_b4b861bc-5fd6-40db-8cb2-cb1a532f0c01_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_abee88e6-c93c-4243-8294-cc3b9e3b67ca_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_2351013b-5264-474a-9ffc-906dc880379d_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_c80e27fc-0fdc-4f5a-9cf9-bafb124c0187_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_b83c715d-34c7-476c-8a52-3e82ce345b1c_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_a876e64c-5572-4078-b7d1-92ecafe8a8c5_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>exel-20241029_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:b3915185-4d70-4139-b9e4-6aa0964ddf94,g:a123f1e6-6f11-4d51-8130-aa9d378b2a84-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.exelixis.com/role/CoverPage" xlink:type="simple" xlink:href="exel-20241029.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_eccdfe5d-97d8-41f7-8d62-213483da5b02" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_44847424-ea59-4c01-97d9-30438d797fad" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_eccdfe5d-97d8-41f7-8d62-213483da5b02" xlink:to="loc_dei_AmendmentFlag_44847424-ea59-4c01-97d9-30438d797fad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_dfec76c9-4d59-4cb3-bc1d-b2a1bf343bbd" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_eccdfe5d-97d8-41f7-8d62-213483da5b02" xlink:to="loc_dei_DocumentPeriodEndDate_dfec76c9-4d59-4cb3-bc1d-b2a1bf343bbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_57401a4d-ff3e-49dd-bafa-a67f335f1c19" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_eccdfe5d-97d8-41f7-8d62-213483da5b02" xlink:to="loc_dei_EntityRegistrantName_57401a4d-ff3e-49dd-bafa-a67f335f1c19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_df700780-b8c7-44d9-a4ec-a6e37a558e6f" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_eccdfe5d-97d8-41f7-8d62-213483da5b02" xlink:to="loc_dei_EntityCentralIndexKey_df700780-b8c7-44d9-a4ec-a6e37a558e6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_2f4e84e7-e51e-4245-a9e5-9a24f7c191eb" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_eccdfe5d-97d8-41f7-8d62-213483da5b02" xlink:to="loc_dei_EntityEmergingGrowthCompany_2f4e84e7-e51e-4245-a9e5-9a24f7c191eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_6680bd98-bbb2-42c7-b0b1-088ddf08150e" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_eccdfe5d-97d8-41f7-8d62-213483da5b02" xlink:to="loc_dei_Security12bTitle_6680bd98-bbb2-42c7-b0b1-088ddf08150e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_2a5126d2-90d0-40ea-ab35-44d037aae73a" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_eccdfe5d-97d8-41f7-8d62-213483da5b02" xlink:to="loc_dei_TradingSymbol_2a5126d2-90d0-40ea-ab35-44d037aae73a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_3562079f-43f4-4163-a89f-db516374acb8" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_eccdfe5d-97d8-41f7-8d62-213483da5b02" xlink:to="loc_dei_SecurityExchangeName_3562079f-43f4-4163-a89f-db516374acb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_fbebffd8-f945-4e21-aed6-ee26625f7c00" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_eccdfe5d-97d8-41f7-8d62-213483da5b02" xlink:to="loc_dei_EntityFileNumber_fbebffd8-f945-4e21-aed6-ee26625f7c00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_9fe60938-3a4a-439c-9c5b-ca8b2de47864" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_eccdfe5d-97d8-41f7-8d62-213483da5b02" xlink:to="loc_dei_EntityIncorporationStateCountryCode_9fe60938-3a4a-439c-9c5b-ca8b2de47864" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_cb5b107f-8864-4950-9052-595debd01846" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_eccdfe5d-97d8-41f7-8d62-213483da5b02" xlink:to="loc_dei_EntityTaxIdentificationNumber_cb5b107f-8864-4950-9052-595debd01846" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_bbba2bfb-7ff3-4fad-ab63-ecc52c982602" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_eccdfe5d-97d8-41f7-8d62-213483da5b02" xlink:to="loc_dei_EntityAddressAddressLine1_bbba2bfb-7ff3-4fad-ab63-ecc52c982602" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_f11d0408-47e6-410a-af00-c180f79905e4" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_eccdfe5d-97d8-41f7-8d62-213483da5b02" xlink:to="loc_dei_EntityAddressCityOrTown_f11d0408-47e6-410a-af00-c180f79905e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_d530a342-5926-4c1b-8ca8-0789bf0a07c4" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_eccdfe5d-97d8-41f7-8d62-213483da5b02" xlink:to="loc_dei_EntityAddressStateOrProvince_d530a342-5926-4c1b-8ca8-0789bf0a07c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_b68ab550-9293-4344-ad7a-d47d7c5796fb" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_eccdfe5d-97d8-41f7-8d62-213483da5b02" xlink:to="loc_dei_EntityAddressPostalZipCode_b68ab550-9293-4344-ad7a-d47d7c5796fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_2af28f6e-3523-462b-9425-2a4774752290" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_eccdfe5d-97d8-41f7-8d62-213483da5b02" xlink:to="loc_dei_CityAreaCode_2af28f6e-3523-462b-9425-2a4774752290" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_c21da975-31bd-4914-9c53-de04c0fbd29f" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_eccdfe5d-97d8-41f7-8d62-213483da5b02" xlink:to="loc_dei_LocalPhoneNumber_c21da975-31bd-4914-9c53-de04c0fbd29f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_649c0b3e-c439-462b-b31c-e9d8d1bf0f42" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_eccdfe5d-97d8-41f7-8d62-213483da5b02" xlink:to="loc_dei_WrittenCommunications_649c0b3e-c439-462b-b31c-e9d8d1bf0f42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_831fdc78-11e1-462c-89b6-47dadee7aeda" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_eccdfe5d-97d8-41f7-8d62-213483da5b02" xlink:to="loc_dei_SolicitingMaterial_831fdc78-11e1-462c-89b6-47dadee7aeda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_3b34b99d-1fe0-476e-81a3-6a790c5d08e2" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_eccdfe5d-97d8-41f7-8d62-213483da5b02" xlink:to="loc_dei_PreCommencementTenderOffer_3b34b99d-1fe0-476e-81a3-6a790c5d08e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_6ed509a6-aab5-4200-9019-611efda330e2" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_eccdfe5d-97d8-41f7-8d62-213483da5b02" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_6ed509a6-aab5-4200-9019-611efda330e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_a3431d18-b411-4623-bfd8-84ba222d0f5a" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_eccdfe5d-97d8-41f7-8d62-213483da5b02" xlink:to="loc_dei_DocumentType_a3431d18-b411-4623-bfd8-84ba222d0f5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>exel-20241029_g1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 exel-20241029_g1.jpg
M_]C_X0TO17AI9@  34T *@    @ # $   ,    !#.0   $!  ,    !"?8
M  $"  ,    #    G@$&  ,    !  (   $2  ,    !  $   $5  ,    !
M  ,   $:  4    !    I $;  4    !    K $H  ,    !  (   $Q  (
M   A    M $R  (    4    U8=I  0    !    [    20 "  (  @ "OR
M   G$  *_(   "<0061O8F4@4&AO=&]S:&]P(#(S+C0@*$UA8VEN=&]S:"D
M,C R,CHP-SHR-2 Q.#HQ,#HR-@      !)    <    $,#(S,: !  ,    !
M  $  * "  0    !   $L* #  0    !   !1P         & 0,  P    $
M!@   1H !0    $   %R 1L !0    $   %Z 2@  P    $  @   @$ !
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MDI__V?_M%2I0:&]T;W-H;W @,RXP #A"24T$!       *AP!6@ #&R5'' (
M  (  !P"!0 617AE;&EX:7-?3&]G;U]21T)?,C R,CA"24T$)0      $.Z*
M+VTF;HFD<OR1I?7(F<@X0DE-!#H      0L    0     0      "W!R:6YT
M3W5T<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT90
M  !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE
M5$585    !0 0P!A &X ;P!N "  :0!8 #8 .  P #  ( !S &4 <@!I &4
M<P      #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %,
M90!T '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U
M:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $
M     !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#
M;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O
M;       3&)L<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;
M26YT<F)O;VP      $)C:V=/8FIC     0       %)'0D,    #     %)D
M("!D;W5B0&_@            1W)N(&1O=6) ;^            !";" @9&]U
M8D!OX            $)R9%15;G1&(U)L=                $)L9"!5;G1&
M(U)L=                %)S;'15;G1&(U!X;$!2            "G9E8W1O
M<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S     %!G4$,     3&5F
M=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP
M    #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N
M9P         -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P
M;&]N9P      .$))30/M       0 $@    !  $ 2     $  3A"24T$)@
M    #@             _@   .$))300-       $    'CA"24T$&0
M!    !XX0DE- _,       D           $ .$))32<0       *  $
M     3A"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H
M!@       0 R     0!:    !@       0 U     0 M    !@       3A"
M24T#^       <   _____________________________P/H     /______
M______________________\#Z     #_____________________________
M ^@     _____________________________P/H   X0DE-! @      !
M   !   "0    D      .$))301$       0     @   D    )      #A"
M24T$'@      !      X0DE-!!H      V$    &              %'   $
ML    !8 10!X &4 ; !I '@ :0!S %\ 3 !O &< ;P!? %( 1P!" %\ ,@ P
M #( ,@    $                          0             $L    4<
M                     0                         0     0
M &YU;&P    "    !F)O=6YD<T]B:F,    !        4F-T,0    0
M5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   4<
M    4F=H=&QO;F<   2P    !G-L:6-E<U9L3',    !3V)J8P    $
M  5S;&EC90   !(    '<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG
M          9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N
M97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4     26UG(     9B
M;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
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M=71S971L;VYG          MR:6=H=$]U='-E=&QO;F<      #A"24T$*
M    #     (_\        #A"24T$%       !     $X0DE-! P     "\$
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M!0$! 0$! 0         #  $"! 4&!P@)"@L!  $% 0$! 0$!          $
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M    % !! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <  @ #( ,  R #(
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M1T(                  /;6  $     TRU(4" @
M                                           18W!R=    5     S
M9&5S8P   80   !L=W1P=    ?     48FMP=    @0    4<EA96@   A@
M   49UA96@   BP    48EA96@   D     49&UN9    E0   !P9&UD9
M L0   "(=G5E9    TP   "&=FEE=P   ]0    D;'5M:0   _@    4;65A
M<P  ! P    D=&5C:   !#     ,<E120P  !#P   @,9U120P  !#P   @,
M8E120P  !#P   @,=&5X=     !#;W!Y<FEG:'0@*&,I(#$Y.3@@2&5W;&5T
M="U086-K87)D($-O;7!A;GD  &1E<V,         $G-21T(@245#-C$Y-C8M
M,BXQ               2<U)'0B!)14,V,3DV-BTR+C$
M                                                 %A96B
M  #S40 !     1;,6%E:(                     !865H@        ;Z(
M #CU   #D%A96B        !BF0  MX4  !C:6%E:(        "2@   /A
MML]D97-C         !9)14,@:'1T<#HO+W=W=RYI96,N8V@
M !9)14,@:'1T<#HO+W=W=RYI96,N8V@
M                                9&5S8P         N245#(#8Q.38V
M+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="
M   N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S
M4D="                             &1E<V,         +%)E9F5R96YC
M92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$
M "Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ
M                                  !V:65W       3I/X %%\N !#/
M%  #[<P !!,+  -<G@    %865H@      !,"58 4    %<?YVUE87,
M     0                        */     G-I9R      0U)4(&-U<G8
M       $      4 "@ / !0 &0 > ", *  M #( -P [ $  10!* $\ 5 !9
M %X 8P!H &T <@!W 'P @0"& (L D "5 )H GP"D *D K@"R +< O #! ,8
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M^!GXJ/DX^<?Z5_KG^W?\!_R8_2G]NOY+_MS_;?___^X (4%D;V)E &1
M 0, $ ," P8               #_VP"$  (" @(" @(" @(# @(" P0# @(#
M! 4$! 0$! 4&!04%!04%!@8'!P@'!P8)"0H*"0D,# P,# P,# P,# P,# P!
M P,#!00%"08&"0T*"0H-#PX.#@X/#PP,# P,#P\,# P,# P/# P,# P,# P,
M# P,# P,# P,# P,# P,# P,#/_" !$( 4<$L ,!$0 "$0$#$0'_Q $/  $
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M P$! A$#$0   +_
M
M
M                                         #%O'^1Z4Y4Y!QL
M
M#X8^^+]SBOS_ *<F?>X_N],@   !T#X_VZT.BO0-K_H?S3O]L0
M                                                      !COXOW
M:W^D.^\4\>Y)JF.?_9^*?_<72<FN=]>@  #A_P WZJI///I2:7:/4TH>?==
M
M    #C\=ZB_.'I[I?R_J@#7,6F^@/.6:.4<3  &B)K-Z)]!]2^=].U_T/YIU
MS
M       C-P3L&N'I'OGX  28YUP"R#N_H0  0:ZG[BA7U=VS:5W]YSS?ROB
M
M     $,^L.UX)]2]Q@ #,_)^*VH^@O-X $:N#<_K=Z/[\D)S/@]F?>WGP
M
M   1[X9SBLOHGT&0 !*OL+KBPWN?HP 8LX_R.JOS[Z1VF6EM_HWS)D/[7P@
M
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M@  11M6ORU(I6C&J/S/LNPPSG$ROK:>=;YUB0!C:8K0O3M4.()YUOG*)
M%'&F4);5      VAZ@L=^U I0TR@;:H L4K>XW/0  #045:Y0VFH M I>V&F
M@%0&F=;MJ      #T69;9UB0(CVK0IIEJ!E5/I,QV     J?OG5_>GP$MHM?
M7EJ!7]TYW=$GKGLSX 2'YIP>S'O7SZ /QK?\*7WNN( %?737=\3.N^R_I.GM
MKIV9W9_4X \]VN,;Y@"VBFEG-+@ =3*5=<H9374   #X3-K:X&FF5(D59WIW
MX_8Z@<2BTVF@    \UFV.,4      =@/3OCON@<.>>W7'!$P!I+K<])[5N
M*NKTJBOG] )91:^G+7]@#SZ:XQIF      /U/33COW, JWOG5->@&54^DS'8
M    "@77*+$U EM%KZ\M0.'_ #?JJ(\W^H.K?/\ H ?$V6=Y] 2-YMP,   "
M)O779E?'3?=_U'=?J?*MW](>7]YKD!M#RT;8?0"VBFEG-+@#B#S[ZXQ]F
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M"VBFEG-+@8<F/-]KCK +#ZWN0STU             \TVV.-T 6KTO:530
M    #IB/._KEC&8 _0_, &?HGT&Y;<L   >?+7&-<P!8M6]Q>>@      JUO
MG51>@&54^DS'8    "@/7*+4U EM%KZ\M0 !MJ:5+^=/3../B?= )GQV_P!+
M3 [*ZM$+>KNV8,]3]Q$#<WI;CZ.\Q]^^Q\0  ; \M6V&L MHII9S2X'#'E[V
MP_, ^&?XF>M;R[K;.$3K           /--MCC= $Q*VEY%@  !VR)GK6P
M$=)CS]:X\<  #M9Z'LMLL1(   \^6N,:Y@"3\6G#6P   W4+%ZW  JUOG51>
M@&54^DS'8    "@/7*+4U EM%KZ\M0  ,+<6Y;5CY_\ 1WQ '*_H_/;KZ/\
M,.*N/\DK-Z)]!:( 2][)ZPGWW!TH  !L#RU;8:P"VBFEG-+@"B33*'-J@ #0
M=R)/UM+F+37K;(<2         /--MCC=      S/$^CK+8    5Z7I3/?/4
M#47NYZS"K8   #SY:XQKF     !S!ZB<=P *M;YU47H!E5/I,QV     H#UR
MBU-0);1:^O+4   5X=+]Z16Z^[& &;N5<1Q3Q[DO#_F_2!S7ZORV_P#I/RYS
M_P"S\0  &P/+5MAK +:*:6<TN ,,3'GKUQZR    :R:-;6P4TS;$@
M#S3;8XW0     ,\Q/HHRV    'YGF^UQQ', "4T6O[RU    'GRUQC7,
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M2J:        8IF//!KCU, Y(V1^0!E)/H?RU[A$@  >?+7&-<P!8M6]Q>>@
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M->0?L_# P=Q/F%7'07HL@#G/U_DMV]'^8.S?O^> !L#RU;8:P"VBFEG-+@
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M*GO/'I;9Y: ;O3.VOT7YER%]KX8V!Y:ML-8-9Z$<MI&Q( ZV53Z9UUVIQP
M !^Y976]L^>FX        *6=,^F3     'TR?$VB4OD6)$/[5KFO0 97B;?\
M]-8   /Q*YKTBG-=C(:2U//21$2*CM,\+S      [Y"SRFF88D 07M2!UZ@
M  #L$+%:WE)6P%36F>"YC<0E)%K**7_4 K^Z<[MB1USV;N;UM'[^\YYHY1Q,
M     8FX[R:(?6W:'7_Q_M S5RGB4R^SNJ1M"B_7+4<O"?5;S(K8  #I$Q!>
MU8BS6/MHQZC9&HY\S=$RVK:P2M\PQ(
M                    Q[\;[E2'G+TYMZ7L)[EZ/EAV)UH
M    !MSB#]CF#Z
M      5H=%^@8[\*YS++L7K2P7N3I
M                                          86XORVJ_S]Z.S5RCB=
MH_?WG/<7H
M                    !IB:I?/7I/JWS_I6P>B/-/9?W?/
M                                                           $
M9^"=@UW]+]Z6I^@O-V5>0\;
M                                   &USTJ(\W^H9U=M=-27YUU^
M
M         !#?K+M7KWXOW3I[:Z<
M                                        &!.(<TSSR[AFJ8
M
M
M                                                       __]H
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MC3+QB;C/,:P5*@C&,8<90ED55\!0*%0D++*BX*3& ("&F?3 PMW8#!G,'Z>
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M5U0ZG%827+'Q%YH3\@^].,B"L'2HMR^(^)H'R%#/LW4&ZAG,._@0XUAQ -V
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M<(JG4>['Z"5F^@E9OH)6:4T%628K'L#=@;L#";?0 =F [ 8&WR]@83L(B/\
MN=?5RI<&=X=X81V:2)7&#)_HV_\ NR>%OW^,:1Y8]Z/[$IN6_A<$ ;-*TN&6
M'[MV5V7V(B.S32M"J1J.DOE2)34YRGP_L2GM;]RA(:&>1#R6T!VCPWL2>O2N
MB+:J=4C),ECX<Z]B=1%K_&ZD66.X^Q0),@WD6   ?\:__]H " $#  $% /\
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M/WPXCO@N*Q$J"?OSOWF@3,8=]4!V8H[X?_1^!W "A^AN=(>=4I=LHANPAME
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M[F:WJ:?+\:$_?'3O7_)W&QC\F\T9"0T?"55IY%4SG+):S4[XJE87*5H-!E
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MR401)^UI-@%YHV\,(+8HZJ"P:[SF3H+N\@19CQ 7DX "LT7=Y-U;->[7L?P
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M0?=IE7*%1ZK#FMQ7Y$T>1-$'0D$9C[5>0VHB2E;M^"+VF]0KUJDL!54  "P
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M7L@Y9H\O4"*.ODA3&HJ7&V2IJ&QDF<\[.Q/XN0]NS?E>U9GHI%*&FN=)#5*
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M%;*2NJ9*(PPO*&(>0),S8#=YACV*2T%HK=G*Q=969(S Z_P]45P:"8C68)P
MD@&S4X[I1I=<O7^W2VB^V*JDH;Q:YQA)!41'!T/,1SJPU,I##4>78LC90HOA
MV8,PS]52J<>J@C77-53L,=V*%.Z<_B&LC2UY(RRAF$&-1>[S*H$]QKY .OJI
ML-A8C!5QP50JC4.P\5OCM!]F4G(S9F*_6&Y9@@S#:8+=34]M:%7C>*<REGZ]
MXQND'#5B<=/-KFG]I0?.-/-KFG]I0?.-/-KFG]I0?.-/-KFG]I0?.-/-KFG]
MI0?.-/-KFG]I0?.-/-KFG]I0?.-/-KFG]I0?.-+9;8^'&:(Y+I6TU#%(TE!N
MHU5,D*LV$^. +XG#E<%/K&^>+TW(X.??.S^,IV3B-^HLWV=#R,F?55\\3/8)
MX**-?]S6+?KLN2G5O2!??*<GULRC=]MNGFT*NC12(2LD3C=9'4X,K ["I&!'
M3R+7F&RS_![K9JA*FBD]2674T;CG1U)5AT'2TYIM3807*+&>F)!>GG3N9H'P
MV,C CM[=AT6T665),ZWV)A;4.#"B@/<M62KVMD:GOF[0.DLT\KU%1.[2U%1*
MQ>221R6=W8ZRS$XD\BLXC76G!H;*ST66U<:I*MEPGG /^DIW%/KBW1V"Y?%9
MO<'0^W?W1Y'%_P"O[=XB.3<LRTM,R99XHAKU;Z@ [BW) J7&#' #>+;LP'0Y
MZ.7NRQK(N..ZP!&/X]!+DS/=_P KD;(K?<)XX?2,!9HB.T4PTACO5;9<^T,0
M"M%=J(4U01T_":(Q:^VT;:14W$')UYR54L55KA0E;O18G:QZH1SJ/_2.GPO(
M6=K3F= "9*>CJ%-3&!MZVF;=FC_YD'X+Q<^^E]\?F[+P5^]E)[B3L<G%S(E!
MUN>\M4F[F.T0+C)>;9",1N =]44PQ*<[IBFW<&BNC!D<8JPYP>3#!3P2U534
MRI!24D"EY9I96"1QQH-;,[$  ;3H]]S)#'-Q-SC!&^89A@PMU-W\5MA?H0G>
ME8=_)TJJ]BXK?':#[,I.RY2^O[3X]#RN"GUC?/%Z;D<'/OG9_&4[)Q&_46;[
M.AY&3/JJ^>)GL*9\M,&[9,T3=7>8D'<T]R(Q$AZ%J ,?;@^NY.88)Z66ZV:[
MTKS4]M0@;ESC7"&3$]ZD@[F0CF .!PTN.8K]6-77>ZR];63GO1AJ2.,>I2->
MY5>8<BT99LZ;URO=2M/ V&*QJ=<DS>QC0%CZ6EGRU:8^KM]FIDIJ?':V[K9V
M]D[$L>V>P7+XK-[@Z'V[^Z/(XO\ U_;O$1R;KDJZ.M%<<1697ON[O/;[C"#U
M,P VJ<2DB^J1F&W B[9+SG:GLV9+))N5M(V)CD0D]744[[)(90-Y'&T;<""!
MV&"X451-07&E8-2W&DD>"HB8:P4FB*NOXCI2V_.$R\4\L1D+)%<F$-WB3GZF
MO482'M3JQ/KQI)49)O?_ /;T48>[Y4KU%/<Z,$X8R0$G>3'4)(RR'UV/X'Q<
M^^E]\?F[+P>IJ&,R24E^_F-1AZF"BIYII6/: '8Y)YY$AAA0O-,Y"JBJ,69F
M.H #62=,]7KA70&@R77W!GI&75!556L5=72QX#JX)Y<61?38 !@!R,N5?$>D
M#-5*U)DB\5##X';[S,=V*6H5M6,BDQQ2'4CGF+!E[%Q6^.T'V92=EX=V&B3K
M*N[YIL]/"G3^^1._Y$4GE<%/K&^>+TW(X.??.S^,IV3B-^HLWV=#R,F?55\\
M3/8<W29PB^$6,T+I+3J0)9)F(%.L)YI.MW=P\QUZ+O\ ?X#>]/L-;1W:$+?;
MQ0&#+-PD(W%*'K*B  ['D4 @\X4KZ?8+E\5F]P=#[=_='D<7_K^W>(CE0T>8
MD>T9EM2/_MK.=$BFLHF;648-@)H6.MHGU':"K8,'ASI9S49>DDW+;GBW*\MJ
MJ 3W(>3#&FD/^G+A[$L->FK7CL[%;\P9>NM78K]:9.NM=ZH)3#4P/THXYCL9
M3BK#4P(TAR!Q ^#VGB?20%Z*KB BI+[#$N+RP)LCG0:Y(AJP[M.YQ5/P'BY]
M]+[X_-V1I)&"(O?,=FE9QCSW;)+9F#,5%\"R;8ZE-VHH[9*5DEJ9T88QRU)5
M<%.M8QW6MB!V*OX#Y#N #2($XG7NF?NDC<!EM,3KL9P09R#B%PCVLV     P
M &H <ED<;R.,&&B<*<]7$2Y_RQ2;UBND[>^7JV0@#>)/?5%.,%EPULN$GK\.
MP\5OCM!]F4G9&=V"(HQ9V.  &TDG2GXZYSMDM!:[?#)'PWMU5&4DJI:A#'+<
MRCC%8UC8I"2,6WF<:@I/)X*?6-\\7IN1P<^^=G\93LG$;]19OLZ'D9,^JKYX
MF>PTV0[94;]IRLXGO10XK+<G7N8S@<"($;_J8^MY&)U ;3I>,RY@DDM9N]&\
M>1HCO*1)M2OF4;48C=12-:XMSKI76FZ4S45SM<\E+<*1]L<T1W6';'.#SC \
MBEKJ"I>CKZ&9*BAK(S@\4T3!D=3T@C2WWU"D5U@'P3,- I_P*R,#?P'K7U.G
ML3Z?8+E\5F]P=#[=_='D<7_K^W>(CEU%!<:2&OH:M#%5T51&LL4J-J*NC@JP
M/."-*FYY#J*GA?>YB7ZB@7X3:'<XD[U#(PZL$G_)= /6Z2RTN5X>(%J0]Q<L
ML2]?*1MQ:AFZN<'M(']/1[=>J"KLEQC8J]ON,$E).&&T=7,J-_=V&@NUHKIK
M7=[34QUEINE,Q2:FJ86#131L-C*1^/8=1TMF9:GJJ?-5J<VK.MOBP"QW"%5)
ME1=HCG0K*FK8=WU)_ >+GWTOOC\W(SY/><UW/+#9/J:""F6W14\@G%9%+(QD
MZ]&P*]6 ,-/.KF;Y+0>"T\ZN9ODM!X+3SJYF^2T'@M/.KF;Y+0>"T\ZN9ODM
M!X+3SJYF^2T'@M!CQ4S-ACK I;?CAVO>3I27VFLM1F[,M"PDHK[F.5:QJ>0>
MKIZ<(E/&P.L,(]X<S=C2Q9<FCFXG9Q@D3+D!P<6^FUI+<YDZ(SW,2GOY.E5;
M2:HJ:B6KJJJ5YZNKG<R2S32L7DED<ZV9V)))VGEVG,>7;C+:+_8:N.NLUSA[
M^">(XJV&PJ1BK*=3*2IU'2*^PQQVW-EE*46=LO*V/P6LW<1+%CW1@G +Q,>;
M%3W2GL/%;X[0?9E)R,UY=O.8[AEJ++MI@N,%5;HX)'E>6<Q%'$ZL, !CJUXZ
M>=7,WR6@\%IYU<S?):#P6GG5S-\EH/!:>=7,WR6@\%IYU<S?):#P6GG5S-\E
MH/!:>=7,WR6@\%I37BX6^MX@WFD99*>HS)*D]+'(AQ5THHDB@)'-OJV'-HJ*
MH55 "J!@ !L '*X*?6-\\7IN1P<^^=G\93LG$;]19OLZ'D9,^JKYXF>P73,!
M*/<W7X)8*1O\VMF!$0PU]RNMV]B#I-4U<[U5752/-5U4AQ>661B\CL>EF))Y
M O5[@9<D6.<?# V(%PJ4P84JGUBZC*1[3G."11(L44:A(XT 5551@  -0 &D
M/$^ST^N%8Z3-T2#68@=R"K/M,1&Y];NGU/)@JJV8IEB_;E#F2/$[L:X^\U6&
MO7"QU^P+:+)&ZR1R -&ZG%6!&(((V@\NY?%9O<'0^W?W1Y'%_P"O[=XB.Q&A
MS3ENUYDHR"OP6YTD-6@#;<%F5@/Q:224.6*S)=7)BWPC+U;+3)O'G^#RF:#\
M00:-+D+BI!5C6109CH#&>T/A-$</Q]3I)+5</)<R449;]_RW41W(%5]5U W*
M@:N;J])+=<J2HM=QB)66W5L,E-4*1MQBE57'Y.5_M*HJ>KLO$RW24,D+,0G\
MQH%:II' V;S()8\>V!^ \7/OI??'YN1QK^L;'XO4_@5VSSF1C,*4"GLMGB8"
M>XU\H/44L./.Q&+-L50S'4-+WGG.%8*W,%_FZVJ*8]3!$NJ&EIU..[%"O<J/
M^8]T3R+7E^PVZ>[WR]U"TEIM5,N]-43."0B#4-@)))P !).&E325,+TU7132
M4U932J5DBFA<I)&ZG6K*P((//R+;GO+@:K6("ES%8=_<CN=N9@TM,QV!QAOQ
M,1W+@<Q;&QYWRC7BXV',%.*BCF(W9$.QXI4UE)(V!1U.Q@1V#BM\=H/LRDY'
M$S[L4?CA[/P4^L;YXO3<C@Y]\[/XRG9.(WZBS?9T/(R9]57SQ,]@EME!-UF7
M,GM)16\J<4GJ\<*J<88@@$=6IZ 3S\B&PV]VI+?3A9\PW@+B*2F)P[GF,LF!
M6,=/='4#I;<OV.D6AM5JA6"CIDYE7:2>=F.)8G6223Z%7;;A3I5T%?"]/64L
M@Q22*52KHPZ"#AI<,LS;\MO/[WE^M?\ SZ&0D)B>=HR"C]L8\_(((!!U$'9I
M)D*]5)DO>6(@UHFD;%JFVX[J#$[6@."'V.Z>GEW+XK-[@Z'V[^Z/(XO_ %_;
MO$1V9[7GK*%JS31,NZJ7"FCE>,'GBE(WXSVT8'2KOW NZRP5<0:5\@7J<RP3
M#6=RBKI.[B;8%68NI]>FE?:;M05%JNUJJ)*2Z6NKC,5135$1W9(I8VUJRG_Y
MPY'#?,D9W7LN:+348^Q-5'&X](HY![1_ >+GWTOOC\W(XU_6-C\7J?P&YY@O
MUPAM5ELU-+672Y5#;L4$$*EW=CT #2:^2--19+L;2TN0\OR8KU-,Q >KF39U
M]3N@MZU=U.8X^BTCMNH@Q9NUI%Q5SU;1%Q!S12X62VU"^^66V3 $(0>]J*@8
M-+SJN$?K\:_CQD.V^^QJ'XGV:F37)$@W1=HT7:\8 $^&U,)-JL2"""#K!&P@
M\@9?S+6,>%F;ZI1?%<EEM-:^")<HQKP0X!:@#:N#[4UQ5%/*D]/.BR03QL&1
MT88JRL,000<01R^*WQV@^S*3D<3/NQ1^.'L_!3ZQOGB]-R.#GWSL_C*=DXC?
MJ+-]G0\C)GU5?/$SRZB.WS]5F3,I:WV, ]U$&7W^I_\ 20ZO9%= HQP PUG$
M^F3Z-MRY8*4UEVNLG5TT6O=11K>60CO8XU[ICT=O#2EL%J7KJAL)KS=64"6L
MJF&#ROT ;$78JX#MGT9&M\"MFG+P>LR])L:4[OOM*3T3*,!T,%.FM61@2&1A
M@RL#@58'80=1'(M69[))U=SL\XF@4DA94V20OAZB5"5/IX\VEHS19I-^BNT
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M0\C)GU5?/$SR:^[W.H6DM]LIY*JMJ7. 2*)2S,?Q#2\9LKPT?\QDW;=2-_\
MQZ./N8(O3"ZVZ6)]%<WYCI=[)]FGPH:20=S<JN(XX$'488B.ZYF;N=@;3 #
M#8.P)GNRTIDOF5XB+K%$I+U-MUL^H;6@.+CV.\.C0%3B",01SCD6[,U-ORT(
M_=;_ $*G^(H9".L&'.T9&^G;&'/I1W.W5*5E!<(4J**JC.*212*&1E/00<>1
M<OBLWN#H?;O[H\CB_P#7]N\1'(CX(T-/5V?+&7(Z:ZW]YXWA-XJIEWZ<Q[P'
M64U/TC4TN/\ ICE*TD:NR:T8@$J>D'FT$>5^)>:+%$-D%-=*DQ#M=5([I_\
M;H$BXN72I"@C>JZ:AG;7TEZ?0QS<7+K3*1@6HZ>AIV_ZDIP=!)G3.=\S81LC
MNM?/4Q#THG<QC\2Z    #  ; !R'D<[J("SMT ;=(KK?:1J7.7$5XKU?:>0
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D%$%P$,8@B50ZQ* JAR1@-8.BHBA$0!411@ !J  &P#_RV?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>imagea.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 imagea.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !+ 1,# 2(  A$! Q$!_\0
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M2W1^V&G2M<6%O*^-\D:NV.F2 3BK-5-)_P"059?]<4_]!%6Z19Y+^TO\;'^
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MM B>ZM-3FX"\<PMW*OP,>N"*_+M3E58C!Q^7>OI3]LC]I(_%KQ*_A?0+D_\
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M'PSX=T[0VN,"5K*V5&<#H"1R1[4M!ZG2W'_'K+_N'^5?B9=?\A*X_P"OEO\
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M6Y^-WQF_Y*WXY_[#=[_Z.:OU2_9]_P"2%^ _^P+:_P#HI:_*WXS?\E;\<_\
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MHR<[(4"#/K@5\SDN35<IJ3M5YH2Z6/J,\SZGG4*;E1Y:D=+WW78_'GXP?O\
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IG-W;U"DVBEHK0@3:*-HI:*5@"BBBF 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45966830612992">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover Page<br></strong></div></th>
<th class="th"><div>Oct. 29, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Oct. 29,  2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">EXELIXIS, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000939767<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock $0.001 Par Value per Share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">EXEL<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-30235<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">04-3257395<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1851 Harbor Bay Parkway<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Alameda<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94502<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">837-7000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( /6 75D'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    " #U@%U9'MV@A.X    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+/
M2L0P$(=?17)O)\TNBJ';B^))07!!\1:2V=U@\X=DI-VW-ZV[740?P&-F?OGF
M&YA61ZE#PN<4(B:RF*]&U_LL==RP U&4 %D?T*E<EX0OS5U(3E%YICU$I3_4
M'D%P?@T.21E%"B9@%1<BZUJCI4ZH**03WN@%'S]3/\.,!NS1H:<,3=T ZZ:)
M\3CV+5P $XPPN?Q=0+,0Y^J?V+D#[)0<LUU2PS#4PVK.E1T:>'MZ?)G7K:S/
MI+S&\BM;2<>(&W:>_+JZN]\^L$YPL:X:7HG;K>"2W\BU>)]<?_A=A%TP=F?_
ML?%9L&OAUUUT7U!+ P04    " #U@%U9F5R<(Q &  "<)P  $P   'AL+W1H
M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03<VEVV[29A.U.
M'X416(UL>621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X
M8-DOV]:[MR_>X%<R)!%!,!FGK_# "J5,7K5::0##.'W)$Q+#W(*+"$MX%,O6
M7.!;&B\CUNJTV]U6A&ELH1A'9&!]7BQH0-!445IO7R"TY1\S^!7+5(UEHP$3
M5T$FN8BT\OELQ?S:WCYES^DZ'3*!;C ;6"!_SF^GY$Y:B.%4PL3 :F<_5FO'
MT=)(@(+)?90%NDGVH],5"#(-.SJ=6,YV?/;$[9^,RMIT-&T:X./Q>#BVR]*+
M<!P$X%&[GL*=]&R_I$$)M*-IT&38]MJND::JC5-/T_=]W^N;:)P*C5M/TVMW
MW=..B<:MT'@-OO%/A\.NB<:KT'3K:28G_:YKI.D6:$)&X^MZ$A6UY4#3( !8
M<';6S-(#EEXI^G64&MD=N]U!7/!8[CF)$?[&Q036:=(9EC1&<IV0!0X -\31
M3%!\KT&VBN#"DM)<D-;/*;50&@B:R('U1X(AQ=RO_?67N\FD,WJ=?3K.:Y1_
M::L!I^V[F\^3_'/HY)^GD]=-0LYPO"P)\?LC6V&')VX[$W(Z'&="?,_V]I&E
M)3+/[_D*ZTX\9Q]6EK!=S\_DGHQR([O=]EA]]D]';B/7J<"S(M>41B1%G\@M
MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7
MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V<
M/!T3$LV4"P9!AI<D)A*I.7Y-2!/^*Z7:_IS30/"4+R3Z2I&/:;,CIW0FS>@S
M&L%&KQMUAVC2/'K^!?F<-0H<D1L= F<;LT8AA&F[\!ZO)(Z:K<(1*T(^8ADV
M&G*U%H&V<:F$8%H2QM%X3M*T$?Q9K#63/F#([,V1=<[6D0X1DEXW0CYBSHN0
M$;\>ACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0'
MHYI9";V$5FJ?JH<T/J@>,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y
M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RS<C'5*^3*=@Y
MG\#L_6@^GO'M^MDDA*^:62TC%I!+@;-!)+C\B\KP*L0)Z&1;)0G+5--E-XH2
MGD(;;NE3]4J5U^6ON2BX/%ODZ:^A=#XLS_D\7^>TS0LS0[=R2^JVE+ZU)CA*
M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D*
MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-#
MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B
M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P
MOFH]M!5.S_Y9K<B?#!%.%@L22&.4%Z9*HO,94[[G*TG$53B_13.V$I<8O./F
MQW%.4[@2=K8/ C*YNSFI>F4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W
MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2
MD 83 <V4R43P H)DIAR F/H+O?(,N2D5SJT^.7]%+(.&3E[2)1(4BK ,!2$7
M<N/O[Y-J=XS7^BR!;814,F35%\I#B<$],W)#V%0E\Z[:)@N%V^)4S;L:OB9@
M2\-Z;ITM)__;7M0]M!<]1O.CF> >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F
M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+
M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5
M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0    (
M /6 75D #%_%3@0  'T0   8    >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL
MI9C];^(V&,?_%2L[39O4DA?>.T"BE-ZAZ[5<Z>Y.F_:#20Q83>S,=DKY[_<X
M0,*T\ 1IE5KB),^7CQ_;W\?N8"O5J]XP9LA[$@L]=#;&I#>NJ\,-2ZANR)0)
M>+*2*J$&FFKMZE0Q&N5!2>P&GM=Q$\J%,QKD]^9J-)"9B;E@<T5TEB14[6Y9
M++=#QW>.-Y[Y>F/L#7<T2.F:+9CY/9TK:+F%2L03)C27@BBV&CIC_^8V:-F
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MA H#E&^J%977DHHM)]W1ZTSO'R:/6D;KW$JY]_!*MAQSCG^T_ %02P,$%
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MO-9.&G_FB^$_7G\!4$L! A0#%     @ ]8!=60=!36*!    L0   !
M         ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " #U@%U9
M'MV@A.X    K @  $0              @ &O    9&]C4')O<',O8V]R92YX
M;6Q02P$"% ,4    " #U@%U9F5R<(Q &  "<)P  $P              @ ',
M 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( /6 75D #%_%3@0
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M2P$"% ,4    " #U@%U9)!Z;HJT   #X 0  &@              @ &Z$0
M>&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " #U@%U999!Y
MDAD!  #/ P  $P              @ &?$@  6T-O;G1E;G1?5'EP97-=+GAM
7;%!+!08     "0 ) #X"  #I$P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="exel-20241029.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="exel-20241029.htm">exel-20241029.htm</File>
    <File>exel-20241029.xsd</File>
    <File>exel-20241029_lab.xml</File>
    <File>exel-20241029_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>exel-20241029_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>17
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "exel-20241029.htm": {
   "nsprefix": "exel",
   "nsuri": "http://www.exelixis.com/20241029",
   "dts": {
    "inline": {
     "local": [
      "exel-20241029.htm"
     ]
    },
    "schema": {
     "local": [
      "exel-20241029.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "exel-20241029_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "exel-20241029_pre.xml"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 3,
    "http://xbrl.sec.gov/dei/2024": 3
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 23,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 23
   },
   "report": {
    "R1": {
     "role": "http://www.exelixis.com/role/CoverPage",
     "longName": "0000001 - Document - Cover Page",
     "shortName": "Cover Page",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exel-20241029.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exel-20241029.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover [Abstract]",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Issuer Tender Offer",
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Tender Offer",
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Soliciting Material",
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Written Communications",
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>18
<FILENAME>0000939767-24-000149-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000939767-24-000149-xbrl.zip
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M$]1E$HO9]\R19@M2_<'0#R<@-XLZ2*Y#/8LU>PN\]EDQV-5B77F>8%(F__L
M\,S46I5S-;-2-,GO5$"T2'ZC$W)+Q?TCG2R;KN,M!#V3'77X>"/NPL=IX%')
MU:Y\Z.S19>+/=JBY+$RBC-V-N(4@AZOM_RUC("=70]Y [X"O8/-<9&Y#F,W_
M/SZ,P[&D:FOD:DZA:%A'L.!/V@&UWB<).>@MA@+8RH?4)VS,W%'$'S!' ZO
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M7"2EOVV+TQG[L=[(GQ#EV[V%FC!,TV%$P@I!0Q@_X=-A?>IWL4*+@%3,GW3
M"NP(R[\*'!U%_5  <=YVFPQ+!\O4^Y=[+^R53;U@578M[%DE';3L14I?9=VR
M-Q]7W3^D8D$O6J67*,?M6K;99X ^+8+M\V1%7 I[T>L"VST7,7W>;,]7%=3D
MS0,0K%YQ6ZDDK'FUK;#%HWD'D>57JTL<I-BW6NYYM0+P:S^ >) GF[*YFI=Y
M\@?K=@6;D#]T\CN3DMUSYN_^O-(W4$_&)UWW+E9?%=^RMV<V"M .EP:.Q>,?
MD4@VIF^Q_)N[C& A7/WQ#+5WG[[U@$\#2N:3Q3SJF6>]CRQ/S<=_FT;]09O:
M_P-02P,$%     @ ]8!=62EQ!O!C @  !@<  !$   !E>&5L+3(P,C0Q,#(Y
M+GAS9,U476^;,!1]SZ_P>)X! TU#U*326E6:E&U5UVI]FPQ<B%6PF>TT]-_7
M=D I;5,M>QI/YMYS[I?/]=EYU]3H$:1B@B\\XH<> IZ+@O%JX=W=7N&9=[Z<
M3,X^87S_Y6:%+D6^:8!K="&!:BC0ENDUTFM OX1\8(\47==4ET(V&"\=[4*T
M3Y)5:XVB,$H&V."5\RQ.R0F9G>"D. UQ0N(49RDD>$IIF$Z3HBC3Y',UIR2*
M2P)3/"T),=@3@F<D#C&E:1&?SK*(SA(7M%-SE:^AH<BTQM6\4PMOK74[#X+M
M=NMO8U_(*HC"D 3WWU8_'=3KL37C#R-TE\EZP,>!=6=4P0"'#NH1W!I8QY2?
MBR:P[9(P2CU$M98LVVBX,G.YA))N:KWP-OS/AM:L9%"8H==@QSH"O'!K*BO0
MWVD#JJ4Y_$72Y00A.PO6M$)JQ-^ECMMC7&G*<]/>;H KD5/M='&08O_PP,/6
MA$F$8^)WJO""?ZAA/^+C:AAXQ]?@@BG(_4H\!@4P-\+WTZM#<'O ]C#.23D7
MVO&MI;>U+>.EV!F,R18^'ZJ_@7)0[1LI]L(E:9H&SFM4Z,A4YE+4\#$X:*5H
M06H&ZJ6,78"UA'+A61GA03Z_6PF^J62 O$DPO@+K-AE &0F[?E?[AH80^JDU
M(92YAQIV(_J?^Z]I=FS_A@+UD8U;XJWQ(U8LO MA'N)K6IG"K/WNYNOA/7<9
M]X0AZA"W@))QYI07NH\@O'^[,7),9*EGP6O"JU ;!<4/OG3GUU?<DWO(!\2<
MUOFF/IZW+^L@K3<.D^PW+1BOVN[_Q3HZPV['EY-G4$L#!!0    ( /6 75G5
MW1!EJJ<  (?8   4    97AE;"TR,#(T,3 R.5]G,2YJ<&?L>P=44]W2Z$D"
MH7=$I(M4D=Y!BG0$I!<!@1 "1DH@"46Z#:4(%D1 I4D5$1#I4A0$!06E*R(J
M4D4ZTN&=!+!\UWO_>^]ZZ[VWUOLVY)S9LV?FS,R>/;OD9*MOZQ.-N'8 VA4
MC(R @P  D /4$ " @1"$^@MX@6S#%-_!"Y0($SXI$/@V'H""%\8=&&2$[-F!
MP2N$#2 EP@"0"6'_ =^'"/W"*TFX OO!SR.(%!%F!C_=%]$ R0[])'CC _4B
M_%&NAP. (/WN_8@+QAG%8W(2@\?@3F*\>:2DQ61XA(P02+07 2,,2$E(22E)
MR"M)R?)(*BA)2BA)R0&$0G(% ,@(=PDI:<DTR$_]TZ"[SR4I2H/MPA!=8+O
M(; =6OBO]D&P/^V#!/YJ'Q3R0\99Z _95%D[\O1V;"3>M_JVO@'41)L<-8W
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M6>-JY>)0]D)LG*YQ'=>:9V:?_>HS5$Y(@OU ;59WW=C;M4L+NM9W5_,7T[<
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M7=,#2ZC3$7G-T0$$"@TTGL#S4R8*>PSAB;+0MK$@[L T 03@!6# #P^ !FP
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MS*'JVY^=-JT?;=!_:./ZX</M.AL!@B%^6+9MGB[A$ 8$6 !M( #,(!Y@V@D
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M?63Y]Y'EWT>6?Q]9_GUD^?>1Y=]'EG\?6?Y]9/G_W)'E]NI^/W']:@T0W^D
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M:#[0+-,RT8K1ZM.ZT(;1WJ(MH^V@G:*CH..G.T+G0!=(ET!70M=.-TE/02]
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M /"@$[5#W(>^$\ZZW?&1DJ]3"'<J''CMSVO<TS$B*OO5XR+CCK[S1F4* P2
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MVEY+$(<[(3+U,0L=+X2]P=%D6=YV7UP=Z#@!#[3A] )V!SE(Q$TEG_7M03)
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M^G8P>3L]11U>_AH+283IXV4Z67GSI]5)'D<[TMINAN^.\>)3'S[/$T/X7\8
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M>^D"8S;6R)-+O##-K\NA^ ?@ ,XV)$8/EXP+.*LX,EY#N$WV3'%/&-'L(H@
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M&YUA.8+ 4)C$<R9=00?J?@7M<J%40^@<VCF;M1W J@[\\:(Q<Q.X<@W*=\[
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M<I6P_ ?)$<%6WM7KMNJK==1&&AX"B?)N;<N+GR)I)T2X-H9QA>BQ1K"IINJ
MQ&GV_PK>_R'VGE7+472RR@2F<5%YW%CQ4NB@X/'M\F6N&9RR?4>7R]S\894&
MIT]WV Z-A?NF,Z#:/"HO\1V;<DA#CZT7K5U4<5L9Z!)$TP$8O(O@_4!4GO3"
MV:5J9-_9E<JCK84"!#V?5-3SSP?HP=<@"6@P=K)N;694],5%A;['6%+M$=!%
MAX9DW-P@22VRMQU&O_3+A'ZOTU3, V7!CE26AQ!&!+RR11-:S!6VJ@[J,*T]
MV/,D_I;Y&GOI^@A988MY?U?8I"KV/N)=$50 P!: (C>QV^@37'A_>1'_3^-
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M<J G*'/$8_(ZAB-D9;1D=\N]$#6A8<J<QWB%-R@].I?O6\PQ^$Z +LY/@61
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M@9G!MT/BQ=0WR AO!@X<[]%%\028U//GQ=W.#\I<_^Z ,ZURNL6\IQ%3W!,
M)3Y(AK-"R[FR=)I\W+XR^PE> X*"UTZ^4[@P+U$U+??AA?*O<+ C-%AJ"P"4
M TGRK%_#^/;.R)!]\'-BI</U5195VI^=32\BMY54,Y(.Z=-G$GXNC7NJ%==&
M91NK4 1GT8"6N&:\0RI"B2- QF,J%LG:(ZXOFOA&G$H)SN]_Z&%PO'7I_OY
MD\+/:3Y^O._Y*+T?SM"FT\0.5^&#(=&2$'ZL(;4C0Z_#VP.](1[!BL#?.,OA
MFI*WB*YD94-U]-S9/.[*9G]#U,+&4'TTW=('_<PB&'C2\>UJ-0F5%,)V/NKM
M:-PO>_XL>3%##$C;5>L27_30B?LP.2W9)',R7&1$3]\-6F'+/-?(ZLW[$_^#
M3# %&\&FUU'F=U1<EWU]+Z[F-=53UDW:FV=U5@  0!C@!' W9GK.'DOG\)IG
MPO"V8- (=?8<'^KP$[+,CI5B$QP(T1$V=IL;^2.GD[+G-TXNTJ^&L,4:+VP
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MFN\X,*1)V'('YQ1M.]-]9S\\_8V.3(UB^W#"18+G+PY$'DCN'9V/K"I.F;C
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MYH0N4:Z[AZDX;?.L/N4$,5=NB&P](JITUV-\4^[;T*YN.U/,0\,(XZOA&,P
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M85B$&-WL^E+MR;$4 FG+..$[)AGMUC'P'M&:VXOY.ZZ*X<GUJ,CEEMO$3CY
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MT;QA];2LE+T]&GB4C=HH-*40D*;EZS7)^8.^TD>=FN0(.(4W/SL1@4F,R]C
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M<57M8./^16V7L?$5;2OJCREGNXSUUK*=C4=B>68./Y>7Q5T^3T.B46*FFHE
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MLU$GI/::\>*J.^)D<.TUU"1L?T/?A>]+=O]1FJB9WDR:-F4^I8R:>HU!S(2
M."4",F' BSC29@Q+0Y$F;FO?/4K3+'\;<=!6]WPBOZ^_ABZ!OT O>*V"NW>
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M:T3E7S\U>RVD70G0>A9!57;%GE!;P,K#$7<>&'SG3T 9H*F7Q"*466+YH&Y
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MRDJ<LA*GK,0I*W$*5(M15N(LJ<1IE)4X^UZ)L[R9 .O#3_$(YE@XXK)&6QE
MTJ*2_FP@4K,O-3MC@RP^LQ5@)'$0V1FCE?O@N#MT/H4>%[KR7)8*3())!KXS
MP!"_I!@VMR<!KFJ"1?"R5T-095<R"VD9D<W]C%$ZL_CE"T435&"<W<%\J/3:
MAH*R/60BXR&Q]*[LN@$FTLV;8UCCRS0L= >7<T0?)RN/375YY SW%J:?]1$"
M$W0<87T.D!&>$9K$'N6,N9\[&J,<0+A7_B:ABK7Y>#P)R(GA82Q9>1[Z L]V
MXLF.J4?&1Z"J*41'X-,J"]U\53L;7%MA< PU6R$>DN!IB-L"#UUB$"/0CT@S
M 7"&-0 )07'JN5N>#KL8 /NA""BH;5+##\PQ^\P:CX5IP:+RF1=<K((1D5[V
M&%6\F3DN00(H;@>N.D/CPY.C@*CP.4[!$W-X4,@FO)-;2S$J#;;NH,!%- H\
M48!I(*3'&$<Q@L?\0620"TXR!;3W.K"T\(S5,]"4!^T2 4+2!='/,8<!2P[Q
M(-L ^[[@X8R(T.G35<DC@'#2!V=IX#F.SY"" %J/,  9I)Q/^1FX/^9I*7'4
M,53)R(1])3WH: D>1P[HDHP M>=!("N:4H<9WH)257[<%^&3$(ZBR:Q,!S&(
M=(2FNUQ=2H9+),27W..#Y/FT,CK &"\SWA]B)Q>1H,.'J!8#J58LRGIAJFF?
MB7?= -:481EW7-AC"#QC85BQ@4#*"(]Z@AOE/N%?\H!W]I1X[G3LP JPAHB.
MS;YZ_6FG6F^ML)$Y@1KT%BN-:G>.BX>Z4J+YJ'Z\BRCXRJT$7TQ+>Q.<:72J
M>D]_=5=9[U4[M=5<Y;4?VWH-#USA!/VM$R >%KBV93(DO5/U%1+RU#=S/9HW
M>/Z*CN'8,DU;+/2+M]V^B@CP7-9/K"6Y7WFAM95DP5'22P/L >7HLMC'/5[9
MR7T>S[Y\Z3NB@5M?/%IN%.P9$9Q%0Y#?K+V8!-Y2IFR [^V&M?.G&+9N;=0V
MMS;8*W+SOG/L?-Q^KP,&:JP?-[5C\(%>2SXHI#2<G_%)H+M5\-6KO4XK#[Y:
M^L%L!NB]RI";.:>(]DF2'.G;]EMJN6-^I0!;S(&=/ ?6JUU]E@-+ ;8(?.V\
M_ =XMF;E?]$$V#9A=(ZGK=P!&[H8]8;%FSFP; <:!:*9'[ZKZ^W39K7U-^J,
MM$2RE_PV#;OFWX#'5@1<D?AMZP;#RJ?^2LVX2+3W]%;:K9I]WP.Q/LZ+];VP
MO!IE3.95R:#3VDLR*.,RTYC=V2G5MT9UZS4Y_D"YNMG)<76K-B/<"R4M"V2"
M?=],%>$BT*TN6U2V;CZ,#L\7NJ2J)90L6,/D9R>,/$MH!0!5@3A8KZ,KH.M_
M6Y=?-P7C03*S7IN&XH):TPSFU<X4K+KQWM2\H I^\EJ[Z*V4C/KOG/\69LYR
MJ^]4]>GETT>OM?Z65-7/;6&QIJ\_5PWRNH<B5X.W;#T_6UR3G,%*^DA,54;Z
M @PK\-<CGWI7V=S)M/"W'/8K=R*LTZ074*?C9UHSY.Y.<M%P]^+2KWR5"'))
MYK0&_GE0!*+OA$"FZ_T(GW,;H26TXV.9;=RSC6I>U=%L1#R7QPR?1JXML!D5
MX\:?D24A(ILY)7VP<.)'5?\;%7H!CD?8[O_S]>7]?[[*Z0KX^Y>K?ZOR853$
M;DIW=:TDGESD8!?$<Q73P/>-U,ZD%O*JL/NY^O'70M_;JK:W1EYSQ\AK[A9Y
M^\Y[K1VCK_W:Z'O94<K,_*\,UMMYN[IH-=GI,,E_PO4VWK//W03F-^J8&8E'
MPV(,%Y5MMEWD6;^/U6UD#N*,FPL_&K(SS[/C.1A'9S<79\<L,SKO;,@M!Y3[
M]=W-5 /(9%(8?'5<W4ECD*O$X-3FOK_/C8>A#]:I65%+&=!_IV^]L*09Y]28
MP?CX4?(Q\/4%"*4G/%%QE/N&;CC&&5W2LI[I$8$XG[_MM]Z=+V@4&] 9H#Z9
M.F2,N&T+1S8P"T>^$.RSM"A_<=T'\!GH-)E'PQES7DFNH^D1@>U6777C5EF]
MKM5Z=:W9Z+$CPY\$(;=I7@P8H030,3:@B"\"C7?DY?N4RGZUI !D.U.ZMJO5
MZBUV-!;AR)5C;D(P7D-T<XXS#2T\"Q"3F*8MM$T;M?G$OC-BNY\AFP0G\1DR
M=3 #G36:PF-AZXW0\B);'=[$(WI99.+(-VKR2W%YR\@C*78A2%P0DO1ZH]OI
M'N/Q)?0KE?>@'@>HTY+?<3@K8D']C5A0-%%E][N@YAGHJ0. Q'@$F&G6RY!H
M3*$Z$%2CV5M.?%:@^O(]<@Q1R:-580(SZG\U%PD$9@7THA&?.P.>!\=] M@-
MA98V)?[HNG+#90>5LH/*IL=>R@XJ90>5LH/*EAR+LH/*<QU4FF4'E=UT4-F9
ML2/]Y4QU"KK,']%CQN8::,M-1,B&X/60:R./Y3\*QCT\JJ6&R&YFX+WUUCYG
M<C>-N%GJK$/*2,^J<]TV^R,RAY09\L7 5CZA;+\!('*=*OLE.^%X@9.2?Y3&
M@I$;V;+S <"6@6BQQK+)AX2CR,$002=7FJ83Y&SQ </Q%$&$!9@Q N1\DF3"
M<J%,:9M'#HZ9=5*S>15ZP1Z*MDW4UQ<X< ,W'SMY.!9UQG_5DOFUX:SUGLZ#
MS73OR4P4I@1C8#U:X60WE+K$W4W(475Q*11ZLT '>A3<WLG8!? QA46-D;#O
MTJ10(#JT9B%X9NR)G<>CCB\R)>#G"R8Y$TO&78+^-S>:&@3#N3ON@[1,[_G7
MY7_NO_QV<08ZNM,\94>>&/=]U[;^BL:\C^$8]D_!I>=](^#IYS2TF?ZF^W^_
M_'3UY?(?\>U]8?\5 9BX0_=^H='4Y]B^YCP937WTY?S\N+H3VLW&>]-V3; 7
M";HCC#S0,.?KNXNYLY$H_<P=;O+C3-T"3Z=1YR<495$$>$FZ-_TUC1=C$5[P
MRU&, 0<Q$/P9\3&>+Y^:^'WTSYL[ *P,CN5?D,44H>7\O,I^HQY#U'A'^.,@
MWF9NT9H"S)-EJ]9MDV1E&K4CPHA>Y?:B4L>;?>Y-TJ;4:JAY"NE*X+E.X/J9
MZ>9W]Y>?/IU]J31JK?RD<YK8K4[24Q\BBJ["G?"N3W4FHS6/U-I(]5R MXY%
MR ,TF0Q&P*#N<+$6RN]%K@0PI\:"__!=LW.JJW=3WZ0G=\$,]AB-:*L\CT@%
M=@DM%RN41Q//_69Q3&E&AH4>\8 #4?H5'70.O!(P>?6QHO_P7:_9.D4V&EE]
M*\18?8RZS$8&$4XE<D3:C2]>M)H +^DA(7:ZR7 K=!\U,ENT?\2@%/.9!TYR
M_:@41>2!0!92)MB;Z88UYG 1IH.HJ_+0=OLRPAE;4W+2B/\@"+;DEU&WK-P+
M#D_&W]%$@"_I1(!;.1%@9SDQV0LB)R)C49>T@C3D]+;$=/K%Y3Z-]+N@!GO8
MYXQ'X<CU:6"=+!Q+-@B711Z-)<D4'J<2*/_D>'0#02D<@5TQ'$E[W:$7@JO1
MD@9\2$&&10,69#.SD#\()SO9C@46UBY=TT$KV3,_%HVR/17>2V0/[TIF!K!T
M(D2N06+Z6I-]7]>KS75V!V\),<,2#ZV@P9 T)T!O5=N961]OK#V?&;=Z((RW
M-.N?S58=<.(_M\^//AAW0/2"8:>"6^4=?LF.YOQ"XR5!K>Q&-LWKH)"?5TDL
MEMW4(-E4UB^6T^!H=FQ^*I(IRUI3:1+/#)&"!MB=M/J2<;33<T-DB]*D@C&V
ME+.+E&GE[_69\:-TIZIVG'MC'"")/"RBS'R3C ^=7[&Y_HC/+&16')63=L&D
ML9P G.GA>S2F<6IBZ<&-+)DMI;V5,%5#4S][L@DFJ,-;96H!M5S=7-ZS6V5X
MWL<F\9GYR$D/WXC(=P'^KN%C+<-]-$:->P0W26*ZB_IC*\0'<RS]"(43*"5T
MY9AQM<YU8FN=*56=N"J(YDMXA2?@_FL!MV"S3W8&E&-,V-'E]=GN7+A?(WL2
M3YS-%(^#"Y!",C5M4VCFS'@-BS/4""@R)@ _!(H\^=,0Q7@ Z- 7<MX*R8"<
M PFJ&>&-#Y +@S4$0CQDPF&I9<NST)8C>M,*9^I:J[ ,"\22:'1H< -'7H)?
M(&F?5Z:_%_("DAN9D)MZ'PW[6^35_LKA855V%A#'QU\G6\YP,S(T,!-Y+B$V
M.C:$],0RHWAEP;?G^G&G<!J2.GV40"$BXU$DXX]A%1,YTQ>ADP)Q$(61+W*;
M,V136RG[@3#)ZTN$TEQ"";+<(;+<8:W.'==G2S '>*#!H#0_4;Y9;H<T3S^.
M:IO@L5HV37G.M/!6!)M4$:FP0=ZO2N=+$35Z-C=$WR6_&=8IWT5?I%YT[$.G
M](54HZ:#RD^(@N9R]N[BGC'_HJV>1! 4OF_B)MTJ,'7EQ,V=CV[.KXZU'#4G
M%R=7D=+^IP %--+4P-3TT>=7Y"9CN!RT5=)Z-@G'W<MP )Y:<1 (P[G!T#+F
MN:ZZQ*1-,H/J+MOO>G[-:4 UIX2:G.4'']SF6.$LQYT%=JX1 CR& '7]QGP-
M;LB8WN$&S+[>;5(BT)!C6E: #?@IZ$E]P='KQ[L!,_0H#HZ#", J\0@YA*W?
M %KLHQ" U9 =W5[\]A'P%>*LVC 6WW'&[0Q\7IO)!&(K\U:LJ(OSHF4)6%D"
M5I: E25@90G8/A0!E25@2TK 6F4)V&$.T7)]#RMG3#1_3($F4^(\SIAPTA56
MAT>0(%*+B^P^'$B<>(PY1Q'OC+TC<J8+Y;@=H&="E69?LBA8'K*[3%/%.=\D
M%\K#NY)A.,H#(/&8!.#N7,,2X82HA8)Q\.C8YV1'EW?7GX_9N>L,_7@:U&W4
MMZU@)$]^O9&C0T\ZL6"SEK$"[("<=YJUVNWNT7.]=(8VA=K<" =]47&>BJSN
M!#)'!0'-Y:_7N]C_[LZ<9H*320!0%K'."P/*D*$W7T( Z^<YW]LEYR_(VKTY
M@A?H'U*A,4A-,78=JKJF8^\HB"-!W6FP)#@-ZQM3<EK.O;3&6  K'--S+:6D
ML3( H Y:O3+ PZI!Y#]:6"/<GS#  04.\5]/4.\"AOZE+X=(6.))4W'7J0&7
M JMJAD,18#&N(P96'*+)+8L;OAO(*IJD\BR(^JCE/>S< U!TA*FI5BS4IT?M
M(,1$$0NL4&@83S'E6$&/IM\%DP#(TC)D49<A ZJJK&L'6;DMV"W+M/QG+,(
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M1!Q[DL*%X58U9KM#T/%P8['P\/3T5!5*6E1!(NPDB:,DB2'2]@F7CY1NY[;
M8[@,XP*RQQ5]>P7&3T!]N'[XKM$]Q;/3 ;42!&JOLK,$]+Y ESR-K.<E$*&5
M3M]B;UC?&-'D1O?-2HOW&46H"K#:!NW7?9:JZUH-9WU,K,?Z=(\W_HRA0$D
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MVC+*,4RP'CET11[/E1,_T&.UQ5!%77/K "'G2SS$A"V-!-GN$8C<42;0F",
M+%GS/Z5GF6M(^T,J1&X"V0<)8Z5&3R;F*J5&W+T19<$4\C(G\6="><_*A558
MBN1<A0+8[!&'@OEI77).,XRY$^&P60J4H]"6 UQ5H#B1LEDN?VXE&7T MX08
M:+7"8$'&2HYTE0]2^D I2:G3\H'6?$8GOA WEZK[A.;P$LIF@4F-.(O-U>GU
MRM<*<THG@ZGK#"7!8K,N5[;!---2;>S@1:L,4JM>(D].[PTRK5S)[ .E0<($
M?Z95F:#>2&C@<O3:Z1>PZ3 MCP^@C^JGN(291;M4J(E1,>Q^%)&3CODZRNIC
M:X9ZK?(OA=)^ *R 5RKW'A L+PZR5_];B[7,],O4KN(L!R8E,\W8[G#@<BHE
M+K])R&'7)U7]4\5Q2<NLVP7G;[)SL7+E1E)+RVEC::^ ),43CXZ9?>;4[.-D
M_BOV(<K(=WRNJL1W?1)H9+!/ENU!98UAM2C-L$4.UMUY(:,9L"2** ]@\Z=7
M+P7-!_)FPZ:O[U[3DU9O^)M6NU"N)H:_[0Y=;<J8CJ=;RCI%59*/-A?VID5>
MS3%QOGQF&3QW#XEZ"R#QKTN:E:YJ^^@XC9P''G^R;-<R3W\'3KBG:K@OW!%(
MDT^?SC6V4H'*[J$@>Z*25+),"\V<9&-R2^=N56)58U_XZ F/J=Q4?X6_?KL[
M6Q_3&Y:?K'S;6P%T*?C@/I!'8<B-D6H4+N.T%'8+*F4*KDS!E2FX!2DXQ+EE
M_OV#9;;:>L/H#O1VL]9L-$27-[H-H]\<M/KZ@/?Y?YL?RK1=F;8K9.*F3-LM
M2=MUR[3=6Z?MWMCJ6=!1^"M8RE^O[L ZO#G?J<V_=)GGGV\N+F_N+B^P=.KN
M\Z>KB[-[^./N'GY<7][<W['/'W$'X.?LU&1?:C\=D4ON1O ,,TA<60]/ZHPH
M5#AV(_!ZCXN[@<CAD6F%PER\QA7<YJVK5KW5VD2U-MK5;F.Q^MQ4M=:;U7I/
MW^BQR[]K2 OB'2^V4>TT]VJQ[=>TL'+*)WMIKS">2&TE:7\_PO3Y-5PW"MAE
MOB$0=JG)N2;O!"8W>*9W19"\E%[22Y5T1FD.UZJFK?$FUP;<V#)-6VP9<#D[
M[H4[?3<0:[P&BQT:4$HR>AD9/2.69N=B&880@\&R[<[S(5]YLZL%S[Y@TCJB
M]&WW=!4Z6;395R.@YZ#YDF>4B]S=(M?F(C5=;HJ+&/W4P3<J*$?=B# IC_ 5
M=TTSUCI[KK%U8U#;W.WW+]K:Z72(L!![:G:Z6JW5FTH2;;"_F%S7V.=:O#CU
MRFE^+JFLT%2FM[5FKU-264EE;[BGNJ;WFEJ]W2CIK*2S-Z6S>J^GM9H[I+-7
M<M,*;V!^HM,;8J%QF>Q=7V_O<YFF.!36KFEZ8UVC; F*WTJ,K>ID'19VFKK6
M:*]KS)38V1)V=)#-O5J]1$\QT5-O-+1FK;T[]+R7V,QY[F@63JFW\)35BS3I
MJN9G@<A-TYO-O?<'#A0Y#:W66E<2E,C9$G(Z6K>KE\@I)G+J':U=VV$\[37]
M3[U5[115B=Y3Q\O7\#X7)I'VB>Q:#8Q[K"L5UH+ 'EG=*^?_"X[59J>N]?3:
M*V.U1.S.$5L')0&H;6[H;96H+3)J&ZV:UEK;?-X6:E_)RRZD4?#9HY;-SI!Z
M;SG!2RJ*U+:?UXT;%;"L:AR_9(7E(M]\D>\EVW/NR@[R0Q?'OP)@S'>2[P%W
MKJ%WRY!U0;'3U3J==8.()7:VY9.V-;U5IGN*BIV:UNGMD'?>2[;GRX(>F.\D
MS:/KNM;JK!O"*,/5VTKT-  ]W5:)GF*BI]VN;Y"3+]&SK4Q<KP?H6=?$*6BV
M9T4ENA- WPG;I@[-<AB<[*S*S;'EJ/'OC^*].*3UNM8MBZ@*BYY&5ZNO7==2
MHF=;YDZK ]RS84*M1,^;YSM!N.GM0W%*:\\KT]#UM@QB"=NKL<<MG[J]NP,:
M;%[!$><F#GD0X7LI06S5M7:GK*0J*':HU[<^W26U1$]!T%,R3Y&QLW/F>2^9
MT2\"'- (QU7 JM^)#]K;X2&1TH!^?;8OT;.U:/MN3UB5V"DT\[RF]UG\VGUW
MIECO)6[GH92/-FL@(]8^P[PN$/;(Z#Z(XQG-;D]KU39L2U&,XQDE2F=ZC;1K
M6JNQ8>Z\1&HQD:ICQGW3MFMOB]1#[@!ZY1CN6+ CVPV"8SF=4-D'KO,VI_OV
MC3(;;:W665?8O,?S0ON$U:-Z1VMU&\>OAM 2F[NT\IJ@.^H;UF:4*"TB2L%N
MKZW='G,K&'TO]=-7V))=!#B6'$V$=Y*:QI,MM?UO_GN@V-$;6KU>YCX+BIU6
M2^NV=UB46V)G:4E[2ZNW=GC@X+TDIC^'(^$KI<F.5(C]6&..V.SHT?[E<X[T
MWMJ.U9[:VGN$%;U;ML\M*&J.FK56R3&%0XO>V&'!^B&WBU%!Y[X8X-!VI2I#
M_JW,1),+VFIJG4TMM<)$G+>1X=HSQ()[5%^WI4F)UL*CM=EK@]];5HX<'&)1
M$#<W[?A;O'YR>Y25OO7=1RO +NU@(;S<0-@_T[/1UCIK4U[I&&Q+XFN=3CGM
MI*#(J==;6G/M,'2)GFU)-EW3UZ[=*YY?3>_NS"_UIK\MQQ0.;+KK%4.EXF#:
M^9G<-RPP+$P?D[6'[JVXZ6+R6+W>T7J=0ZYZ+FGVX&A6JS4WS!V7%%M2["XL
MF>X+>L25-%O2["ZDK [F=_.U8Y7[%,_:"=A3XYMYPF?!B/MB\PD)LV6N#8"Y
MZ49]6[S"B(15_=)RB05=XK93QZ;U&#];/:*"UP-S4)76EGGM%QY81L)7L+;-
MRMP.3&OM@6ZJ53=U /;(9"I);+<DMG8/RI+$2A);R\*N-DHI5I+8VTJQQH9E
M1 7RTPI?QW]AV5$H9N9MO3@5MX>L,6]K166-YOXWF2Y)K-@D=@!]S$L2*S*)
MU:L',/JP)+$BD]@&-F3QBG *:3?^3G\(L\)A-7PH8(/CL>O(H'_ W"@,0N[@
M-EX\(_E%P>7R&=M]QGOQF_+Q]\,N9M2[+:VMEW7:!45/ TN!RZ;I146/WJMK
MW?8.:X%+]"ROU*YKC;6K2(MG)19>8RZ(-*Y$5JL&Y(M#5LCUS<X. ]AEFZ#E
M.K.W>858B9ZWYYZVUEM[?'R)GJWIS*:FKWTV<'O9.=,*/)M/3AS7$<LQ6EZ9
MO[($; G8_;JR!&P)V/VZL@3L6P+VQY#W;1'71"\LVNYZ^1/,%?Q$F5$__]3'
M!RFS9BO/:;0W?D[&<OHC"D)K,%GI-F70M9KP8L\-+!R%<>(+FX?6HSA]LLQP
MI*R][%W2##NII;?P?N"B8[_PEH7KVX*UJJ<SJ6?_70^B1%8I&.BL JS<YEX@
M3N)?3F.RM!Q:!]UT.N;^T'(J"G:MV:/R]$+Y=0K&:DV"4DD*]6;U=96^FC*Y
MY7>];K576_QUK5K_VXJ2:$D>TA#8-[T0SHA$9H6-L<M>A>7<D3D2(?LOXMPR
M__[!,EMMO6%T!WJ[66LV&J++&]V&T6\.6GU]P/O\OYT/\3TC/P7/4%3ZON /
M%3X :)QP^XE/@CSUCP'Q:KD='?:S-I<LYV)%6GAHID?R8KMDVNM5N[W>)E3:
MZE1[K<Y*5+K.8QNPH&;CC8E_:<D&8>AMZ+\SE_XOOPG;^F8%['YD^2;[=\1]
M($:FU_0F^V@YW#$L;K,O(HCL,,@3TA+]^H+MSR%I<NG?3"[,A\LM5B7TF#M@
MO3F[/A3L?S9"MR]\*03UGD9X7QO+LRG\>4)S/FZE*M@><DFG7WZ]_'3U]>I.
M8U<WY]55-/E.EOGE\OSSS?G5IZNS^ZO/-^SS1_:/L[-;=G-YC^O^?'W)[C^S
MF\\WE>F/"["C^<;4D>6P<.1&\ PST)CX9@@O3(_[,CYV(R<,CHN[@<CAD6F%
MPEQIC>LHX_VV&QOM:JO9?76-7&]6=7TS1;_\NT:OM3^+;36;K[_81K737<W0
M+P!D<;&KP6!%U;PPU](KC -36TE)W(]\(=@U7#<*V"6X_R:[ Z$JQJ#76:.F
MK5 [>7 PN8%/5@7)2^DED]];HYOM\X![Y2J+U0"7,_]>N--W ['&:[#8H0&E
M)*.7D=$A=ZXF=\59O]?FJTQ-+@P4UCXQL_J^GZV'V,F&-^NX^793HA,@O&:=
M:TF\!TJ\&[3>+$GW($XJOB+I[E$/SK<CWIV<I"V)=S^)=[-FG-LBWBV=T=T)
MY,],#$./P4<*RD.X[^D9VVXR6ZS6F'>A:SQ4^CP0N/LQ3B;F6*K$*LP7@>"^
M,6+<,9DI'H7M>L@?3 TP3O+CK[+>5K7;6F'%<\JO4-Y5&M7ZG)P/[@N?\.'G
MH_KQ,XG>PSJIU]4Z[76/A)3'*+>FY;7F+GMME-A9>IZJKG4;)>\4%3LM3>_L
M<&SYMFW@O3$70-/"]4.-#84C?&Z3V<#-L>580>B3JGZ'EL/^G5>L-S6]M2Z#
ME:=)MR7^NEIM[7Z6)7:VA)UF2VNW-AS_4V+GK;'3:H-3M$/>V4&[KYW ^2H9
MSLQ@^<((L:X\' G&^RX8 3R-M+V3GF!'+:W1:!V7SD3A$-/3FGJM1$SQ$%/'
M+GK-$C,%Q$Q/J[7UG6#FD/-/-ZY3V;123&VSG+VX=[,7&R#FUAY,O];.=^Q*
ME#1[:#3;T+5:;\/X4$FR)<GN(BS3:&AZ9]V>S"7-EC2[0].@V])T?<.NCN58
MYE<ZK%'.9BZ7^-9+?"\]K>=.@7AQ>J$PDN,PQTJ6\Y=+$GMC$BOG+Y<D]K:F
M=#E_N22QMY9BY?SEK4U%>7GQYZ$PR#X-ERRG,)<D5C1+LB2QDL3**<PEB16(
MQ-[%%.:B5-B\1GC_&;^M?$8!G_%>'*;U0NZE_"_ GL!1VK#]1VEBE"2V(HG5
M2T>I)+&W=92:I:-4DMC;2K'6_CM*A;<@5<B=E74;^Y6..H!QW26)%9O$UC8B
M2Q(K26Q-(W+_>RF4)%9D$@,C<H>*\I"G'OQ.?PBSPF$U.%W0<,=CUY'1]H"Y
M41B$W,%MO+BROBB%W^4S5GC&>W&<YH;>DPT?5F,=O8O=&C8\7U<@77V@Z&G4
M6UJSM_^FU(&B1^_5M6Z[5:*GF.AIZ'6ML?8<G^)9B877F"K4^$YZ@B'7-SO[
MGR0Y4/0TZKW-!W&4Z'E[[FEKO5[9I+N@Z&GH34WO[)![2&?^2)/!?YZ=/:[>
MH!II=V,H6HXIG/"D@I]\6&6&^>K/>3'@>\_!G>9J_G?.?ZNMOE/5IY=/'[W6
M^E=ITJV_J$EWDJ+<(KRQI-3@P0A>MZ ONNIXSB+\9N#ZC"I0?>&YL!-GR"R'
M<<-P?9,[AF!/5CAB9_!WY-"W=Q@BX[X9L'/7M :P=7KHO>M9!NO4N]H;;9H>
M=&*%<+6Q AC.,SO^X;NN7M=/J5$\RWZQ _147X%S7TL"+'^.6G:K"4^890$U
M%9Y$:_8N*?-.:NDMO!^X:$4OO"4C1K$+KS68+%Y?[M^^:T[@QR@<VS__?U!+
M 0(4 Q0    ( /6 75G(</M$+!   -]I   1              "  0    !E
M>&5L+3(P,C0Q,#(Y+FAT;5!+ 0(4 Q0    ( /6 75DI<0;P8P(   8'   1
M              "  5L0  !E>&5L+3(P,C0Q,#(Y+GAS9%!+ 0(4 Q0    (
M /6 75G5W1!EJJ<  (?8   4              "  >T2  !E>&5L+3(P,C0Q
M,#(Y7V<Q+FIP9U!+ 0(4 Q0    ( /6 75DA_PL9,PH  'U5   5
M      "  <FZ  !E>&5L+3(P,C0Q,#(Y7VQA8BYX;6Q02P$"% ,4    " #U
M@%U9&E"A*Z8&  #J,   %0              @ $OQ0  97AE;"TR,#(T,3 R
M.5]P<F4N>&UL4$L! A0#%     @ ]8!=6? LNX(A.0  BG$" !H
M     ( !",P  &5X96PR,#(T,#DS,&5X:&EB:70Y.3$N:'1M4$L%!@     &
-  8 C@$  &$% 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>exel-20241029_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="exel-20241029.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <startDate>2024-10-29</startDate>
            <endDate>2024-10-29</endDate>
        </period>
    </context>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-21">2024-10-29</dei:DocumentPeriodEndDate>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-22">0000939767</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c-1" id="f-23">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="c-1" id="f-1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-2">2024-10-29</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="c-1" id="f-3">EXELIXIS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-4">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">000-30235</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-6">04-3257395</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-7">1851 Harbor Bay Parkway</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-8">Alameda</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-9">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-10">94502</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-11">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-12">837-7000</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="c-1" id="f-13">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c-1" id="f-14">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c-1" id="f-15">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c-1" id="f-16">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="c-1" id="f-17">Common Stock $0.001 Par Value per Share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-18">EXEL</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-19">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-20">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
